| 1 | Biomarkers of Lung Congestion and Injury in Acute Heart Failure | 3.1 | 12 | Citations (PDF) |
| 2 | Connecting the Dots: A Narrative Review of the Relationship Between Heart Failure and Cognitive Impairment | 3.1 | 13 | Citations (PDF) |
| 3 | Examining the Clinical Role and Educational Preparation of Heart Failure Nurses Across Europe. A Survey of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP) of the ESC | 7.3 | 9 | Citations (PDF) |
| 4 | Decongestion and Outcomes in Patients Hospitalized for Acute Heart Failure | 4.4 | 20 | Citations (PDF) |
| 5 | Cardiac Remodelling in the Era of the Recommended Four Pillars Heart Failure Medical Therapy | 3.1 | 17 | Citations (PDF) |
| 6 | Prognostic Role of TAPSE to PASP Ratio in Outpatients with Left Ventricular Systolic Dysfunction | 3.1 | 11 | Citations (PDF) |
| 7 | Increasing Evidence Supports the Benefits of Rapid Uptitration of the Neurohormonal Blockade in HFmrEF/HFpEF Patients With AHF | 1.8 | 2 | Citations (PDF) |
| 8 | Heart failure with supranormal ejection fraction: clinical characteristics and outcomes compared to mildly reduced and preserved ejection fraction | 2.8 | 10 | Citations (PDF) |
| 9 | Therapeutical approach of tricuspid regurgitation and right heart failure. | 2.2 | 2 | Citations (PDF) |
| 10 | Effect of Uptitration of Recommended Heart Failure Medications on Restricted Mean Survival Time in STRONG-HF | 4.4 | 0 | Citations (PDF) |
| 11 | Impact of SGLT2 inhibitors on endothelial function and echocardiographic parameters in dilated cardiomyopathy | 1.2 | 9 | Citations (PDF) |
| 12 | Timing of Cardiac Resynchronization Therapy Following Stable Medical Therapy in Patients With Heart Failure | 4.4 | 7 | Citations (PDF) |
| 13 | Current Treatment of Heart Failure with Preserved Ejection Fraction | 2.5 | 6 | Citations (PDF) |
| 14 | Role of Ejection Fraction in Patients at Risk for Advanced Heart Failure: Insights from the HELP-HF Registry | 3.1 | 8 | Citations (PDF) |
| 15 | Guideline-Directed Medical Therapy in Severe Heart Failure with Reduced Ejection Fraction: An Analysis from the HELP-HF Registry | 7.3 | 53 | Citations (PDF) |
| 16 | Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials | 4.0 | 11 | Citations (PDF) |
| 17 | Cell Therapy Improves Quality-of-Life in Heart Failure: Outcomes From a Phase III Clinical Trial | 4.1 | 7 | Citations (PDF) |
| 18 | Prognostic role of mitral regurgitation in patients with advanced heart failure | 2.7 | 14 | Citations (PDF) |
| 19 | Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies | 4.4 | 25 | Citations (PDF) |
| 20 | Atrial fibrillation before and after transcatheter aortic valve implantation: an intertwine between survival and quality of life | 1.2 | 1 | Citations (PDF) |
| 21 | Obesity, Heart Failure with Preserved Ejection Fraction, and the Role of Glucagon-Like Peptide-1 Receptor Agonists | 3.1 | 45 | Citations (PDF) |
| 22 | Epidemiology, Pathophysiology, Diagnosis and Management of Chronic Right-Sided Heart Failure and Tricuspid Regurgitation. A Clinical Consensus Statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC | 7.3 | 77 | Citations (PDF) |
| 23 | Right ventricle assessment before tricuspid valve interventions | 1.2 | 15 | Citations (PDF) |
| 24 | 2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure | 7.3 | 396 | Citations (PDF) |
| 25 | Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction | 4.4 | 24 | Citations (PDF) |
| 26 | Medical Therapy of Cardiogenic Shock: Contemporary Use of Inotropes and Vasopressors | 7.3 | 49 | Citations (PDF) |
| 27 | Blood Pressure and Intensive Treatment Up-Titration After Acute Heart Failure Hospitalization: Insights from the STRONG-HF Trial | 7.3 | 11 | Citations (PDF) |
| 28 | Quality of life in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: tools and evidence | 1.2 | 19 | Citations (PDF) |
| 29 | Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis | 1.4 | 18 | Citations (PDF) |
| 30 | Functional Mitral Regurgitation and Heart Failure With Preserved Ejection Fraction: Clinical Implications and Management | 1.8 | 17 | Citations (PDF) |
| 31 | Intramyocardial abscess and endoventricular thrombosis: a complex case | 1.2 | 1 | Citations (PDF) |
| 32 | Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries | 4.0 | 17 | Citations (PDF) |
| 33 | Eligibility for omecamtiv mecarbil in a real-world heart failure population: Data from the Swedish Heart Failure Registry | 2.3 | 0 | Citations (PDF) |
| 34 | Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk | 4.4 | 5 | Citations (PDF) |
| 35 | Efficacy and safety of trans-catheter repair devices for mitral regurgitation: A systematic review and meta-analysis | 2.2 | 3 | Citations (PDF) |
| 36 | Impact of Malnutrition in Patients with Severe Heart Failure | 7.3 | 40 | Citations (PDF) |
| 37 | Guideline-Directed Medical Therapy and Survival After TEER for Secondary Mitral Regurgitation With Right Ventricular Impairment | 3.0 | 6 | Citations (PDF) |
| 38 | Management of cardiac sarcoidosis | 2.2 | 72 | Citations (PDF) |
| 39 | Global epidemiology of heart failure | 35.5 | 420 | Citations (PDF) |
| 40 | Tricuspid Regurgitation in Patients With Heart Failure and Preserved Ejection Fraction | 2.3 | 51 | Citations (PDF) |
| 41 | Distinct Comorbidity Clusters in Patients With Acute Heart Failure | 4.4 | 13 | Citations (PDF) |
| 42 | Contemporary Role of Positron Emission Tomography (PET) in Endocarditis: A Narrative Review | 2.5 | 14 | Citations (PDF) |
| 43 | Impact of heart failure severity on the mortality benefit of mitral transcatheter edge-to-edge valve repair | 2.8 | 2 | Citations (PDF) |
| 44 | Assessing aortic flow with doppler echocardiography in cardiogenic shock: A crucial diagnostic tool | 0.9 | 7 | Citations (PDF) |
| 45 | Decongestion in Acute Heart Failure: Is It Time to Change Diuretic-Centred Paradigm? | 7.3 | 28 | Citations (PDF) |
| 46 | Mitral regurgitation evolution after transcatheter tricuspid valve interventions—a sub-analysis of the TriValve registry | 1.4 | 9 | Citations (PDF) |
| 47 | Heart failure with preserved ejection fraction: underdiagnosed and undertreated in patients with tricuspid regurgitation | 2.2 | 9 | Citations (PDF) |
| 48 | Heart Transplant Recipients: A New Test for Gliflozins | 2.1 | 3 | Citations (PDF) |
| 49 | Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia | 4.4 | 4 | Citations (PDF) |
| 50 | GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction | 3.3 | 40 | Citations (PDF) |
| 51 | Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review | 2.3 | 14 | Citations (PDF) |
| 52 | Reply to the letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’ | 7.3 | 1 | Citations (PDF) |
| 53 | Albuminuria as a marker of systemic congestion in patients with heart failure | 2.2 | 61 | Citations (PDF) |
| 54 | Reply to the Letter Regarding the Article ‘Clinical Implications of Left Atrial Changes After Optimization of Medical Therapy in Patients with Heart Failure’ | 7.3 | 0 | Citations (PDF) |
| 55 | January 2023 at a Glance: Focus on Acute Heart Failure and Medical Therapy | 7.3 | 0 | Citations (PDF) |
| 56 | Concomitant Transcatheter Edge-to-Edge Treatment of Secondary Tricuspid and Mitral Regurgitation | 3.0 | 31 | Citations (PDF) |
| 57 | Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry | 4.0 | 6 | Citations (PDF) |
| 58 | Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure | 2.3 | 10 | Citations (PDF) |
| 59 | Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction | 4.4 | 3 | Citations (PDF) |
| 60 | February 2023 at a Glance: Focus on Pathophysiology and Treatment | 7.3 | 0 | Citations (PDF) |
| 61 | Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry | 2.2 | 8 | Citations (PDF) |
| 62 | Impact of Mitral Regurgitation in Patients with Acute Heart Failure: Insights from the RELAX-AHF-2 Trial | 7.3 | 13 | Citations (PDF) |
| 63 | Impact of Transcatheter Edge-to-Edge Mitral Valve Repair on Guideline-Directed Medical Therapy Uptitration | 3.0 | 55 | Citations (PDF) |
| 64 | Coronary artery disease and TAVI: Current evidence on a recurrent issue | 1.7 | 8 | Citations (PDF) |
| 65 | March 2023 at a Glance: Pathophysiology, Medical Therapy and Devices | 7.3 | 0 | Citations (PDF) |
| 66 | Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials | 2.4 | 39 | Citations (PDF) |
| 67 | Aortopathies: From Etiology to the Role of Arterial Stiffness | 2.5 | 14 | Citations (PDF) |
| 68 | Association Between a Hospitalization for Heart Failure and the Initiation/Discontinuation of Guideline-Recommended Treatments: An Analysis from the Swedish Heart Failure Registry | 7.3 | 25 | Citations (PDF) |
| 69 | May 2023 at a Glance: Focus on Pathophysiology, Comorbidities and Devices | 7.3 | 0 | Citations (PDF) |
| 70 | Heart Failure Diagnosis in the General Community – Who, how and When? A Clinical Consensus Statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) | 7.3 | 37 | Citations (PDF) |
| 71 | Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function | 4.2 | 16 | Citations (PDF) |
| 72 | April 2023 at a Glance: Focus on Diagnosis and Comorbidities | 7.3 | 0 | Citations (PDF) |
| 73 | Transcatheter edge‐to‐edge mitral valve repair for post‐myocardial infarction papillary muscle rupture and acute heart failure: A systematic review | 1.7 | 5 | Citations (PDF) |
| 74 | Cardiac contractility modulation: an effective treatment strategy for heart failure beyond reduced left ventricular ejection fraction? | 3.3 | 8 | Citations (PDF) |
| 75 | NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial | 2.2 | 62 | Citations (PDF) |
| 76 | Prevalence, Clinical Characteristics and Outcomes of Heart Failure Patients with or Without Isolated or Combined Mitral and Tricuspid Regurgitation: An Analysis from the ESC-HFA Heart Failure Long-Term Registry | 7.3 | 72 | Citations (PDF) |
| 77 | Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis | 1.4 | 30 | Citations (PDF) |
| 78 | Prognostic role of tricuspid annular plane systolic excursion/pulmonary artery systolic pressure ratio in patients hospitalized for acute heart failure | 1.2 | 11 | Citations (PDF) |
| 79 | Efficacy of SGLT2-inhibitors across different definitions of heart failure with preserved ejection fraction | 1.2 | 14 | Citations (PDF) |
| 80 | June 2023 at a Glance: Focus on Worsening Heart Failure, Heart Failure with Preserved Ejection Fraction and Valvular Heart Disease | 7.3 | 7 | Citations (PDF) |
| 81 | Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events | 4.4 | 42 | Citations (PDF) |
| 82 | July 2023 at a Glance: Heart Failure with Preserved Ejection Fraction and Comorbidities | 7.3 | 0 | Citations (PDF) |
| 83 | August 2023 at a Glance: Focus on Epidemiology and Medical Therapy | 7.3 | 0 | Citations (PDF) |
| 84 | 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure | 2.2 | 2,100 | Citations (PDF) |
| 85 | Treatment of aortic stenosis in dialysis: a necessary update in a challenging population | 1.2 | 0 | Citations (PDF) |
| 86 | Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial | 4.4 | 25 | Citations (PDF) |
| 87 | September 2023 at a Glance: Focus on Acute Heart Failure and Health Status | 7.3 | 0 | Citations (PDF) |
| 88 | Incidence, Risk Assessment and Prevention of Sudden Cardiac Death in Cardiomyopathies | 7.3 | 31 | Citations (PDF) |
| 89 | Multiomics Analysis Provides Novel Pathways Related to Progression of Heart Failure | 2.3 | 42 | Citations (PDF) |
| 90 | Acute Heart Failure Is a Malignant Process: But We Can Induce Remission | 4.0 | 31 | Citations (PDF) |
| 91 | Inflammation in acute heart failure | 2.4 | 44 | Citations (PDF) |
| 92 | October 2023 at a Glance: From Prevention to Diagnosis, Prognosis and Treatment of Acute Decompensation and Comorbidities | 7.3 | 0 | Citations (PDF) |
| 93 | Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide | 1.4 | 38 | Citations (PDF) |
| 94 | Right ventricular thrombosis: from a case report to pathophysiology mechanisms and current treatment options | 1.2 | 0 | Citations (PDF) |
| 95 | November 2023 at a Glance: Focus on Cardiogenic Shock, Post-Discharge Outcomes and Cardiomyopathies | 7.3 | 0 | Citations (PDF) |
| 96 | December 2023 at a Glance: Focus on Medical Therapy in Chronic and Acute Heart Failure | 7.3 | 1 | Citations (PDF) |
| 97 | Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology | 2.0 | 27 | Citations (PDF) |
| 98 | ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up | 2.2 | 139 | Citations (PDF) |
| 99 | Punto de corte óptimo del antígeno carbohidrato 125 para la identificación de pacientes con bajo riesgo tras un ingreso por insuficiencia cardiaca aguda | 1.1 | 16 | Citations (PDF) |
| 100 | Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF | 5.5 | 17 | Citations (PDF) |
| 101 | A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization — the first insight from the AC-TIVE Study | 2.0 | 44 | Citations (PDF) |
| 102 | European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis | 2.2 | 102 | Citations (PDF) |
| 103 | Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure | 11.1 | 103 | Citations (PDF) |
| 104 | Pathophysiological pathways in patients with heart failure and atrial fibrillation | 5.5 | 13 | Citations (PDF) |
| 105 | Diagnostic and prognostic value of low QRS voltages in cardiomyopathies: old but gold | 2.0 | 36 | Citations (PDF) |
| 106 | Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the
DIAMOND
trial | 7.3 | 43 | Citations (PDF) |
| 107 | Worsening renal function in acute heart failure in the context of diuretic response | 7.3 | 76 | Citations (PDF) |
| 108 | Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure | 7.3 | 20 | Citations (PDF) |
| 109 | Transcatheter Edge-to-Edge Repair in COAPT-Ineligible Patients: Incidence and Predictors of 2-Year Good Outcome | 2.6 | 25 | Citations (PDF) |
| 110 | Predictors of optimal procedural result after transcatheter edge‐to‐edge mitral valve repair in secondary mitral regurgitation | 1.7 | 25 | Citations (PDF) |
| 111 | Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction | 7.3 | 110 | Citations (PDF) |
| 112 | Sex-related differences in patients with coronavirus disease 2019: results of the Cardio-COVID-Italy multicentre study | 1.2 | 6 | Citations (PDF) |
| 113 | Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study) | 1.8 | 19 | Citations (PDF) |
| 114 | European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology | 7.3 | 57 | Citations (PDF) |
| 115 | Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology | 7.3 | 58 | Citations (PDF) |
| 116 | January 2022 at a glance: time for the new
ESC
guidelines on heart failure | 7.3 | 0 | Citations (PDF) |
| 117 | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure | 7.3 | 1,971 | Citations (PDF) |
| 118 | Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction | 11.4 | 16 | Citations (PDF) |
| 119 | Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure | 4.2 | 15 | Citations (PDF) |
| 120 | European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis | 5.5 | 36 | Citations (PDF) |
| 121 | Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials | 4.4 | 6 | Citations (PDF) |
| 122 | February 2022 at a glance: focus on pathophysiology and acute heart failure | 7.3 | 0 | Citations (PDF) |
| 123 | Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology | 7.3 | 63 | Citations (PDF) |
| 124 | Prevalence and Rate of Resolution of Left Atrial Thrombus in Patients with Non-Valvular Atrial Fibrillation: A Two-Center Retrospective Real-World Study | 2.5 | 12 | Citations (PDF) |
| 125 | Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure
Association of the European Society of Cardiology | 7.3 | 130 | Citations (PDF) |
| 126 | March 2022 at a glance: focus on medical therapy, prevention and comorbidities | 7.3 | 1 | Citations (PDF) |
| 127 | Advanced Heart Failure: Guideline-Directed Medical Therapy, Diuretics, Inotropes, and Palliative Care | 3.1 | 80 | Citations (PDF) |
| 128 | Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency | 7.3 | 22 | Citations (PDF) |
| 129 | Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure | 2.8 | 28 | Citations (PDF) |
| 130 | Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency | 7.3 | 13 | Citations (PDF) |
| 131 | Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial | 2.2 | 16 | Citations (PDF) |
| 132 | Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF | 4.4 | 21 | Citations (PDF) |
| 133 | Biomarker Changes as Surrogate Endpoints in Early-Phase Trials in Heart Failure with Reduced Ejection Fraction | 3.1 | 14 | Citations (PDF) |
| 134 | Effect of Chronic Kidney Disease on 5-Year Outcome in Patients With Heart Failure and Secondary Mitral Regurgitation Undergoing Percutaneous MitraClip Insertion | 1.8 | 12 | Citations (PDF) |
| 135 | Surrogate markers of gut dysfunction are related to heart failure severity and outcome–from the BIOSTAT-CHF consortium | 2.9 | 11 | Citations (PDF) |
| 136 | ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up | 5.5 | 40 | Citations (PDF) |
| 137 | The ‘Ten Commandments’ of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure | 2.2 | 230 | Citations (PDF) |
| 138 | Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities? | 7.3 | 67 | Citations (PDF) |
| 139 | Prevalence, Characteristics, and Outcomes of COVID-19–Associated Acute Myocarditis | 18.0 | 198 | Citations (PDF) |
| 140 | Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the
AC‐TIVE
study, an
Italian nationwide survey | 7.3 | 88 | Citations (PDF) |
| 141 | Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica | 1.1 | 105 | Citations (PDF) |
| 142 | Clinical implications of low estimated protein intake in patients with heart failure | 9.1 | 25 | Citations (PDF) |
| 143 | Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology | 2.7 | 21 | Citations (PDF) |
| 144 | April 2022 at a glance: focus on prevention, acute heart failure and heart failure with preserved ejection fraction | 7.3 | 1 | Citations (PDF) |
| 145 | Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology | 7.3 | 48 | Citations (PDF) |
| 146 | Prognostic Significance of Serum Potassium in Patients Hospitalized for Acute Heart Failure | 3.1 | 13 | Citations (PDF) |
| 147 | Applications of artificial intelligence and machine learning in heart failure | 2.2 | 91 | Citations (PDF) |
| 148 | Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure | 7.3 | 15 | Citations (PDF) |
| 149 | Head‐to‐head comparison between recommendations by the
ESC
and
ACC
/
AHA
/
HFSA
heart failure guidelines | 7.3 | 27 | Citations (PDF) |
| 150 | Old and new equations for maximal heart rate prediction in patients with heart failure and reduced ejection fraction on beta-blockers treatment: results from the MECKI score data set | 2.0 | 29 | Citations (PDF) |
| 151 | May 2022 at a glance. Focus on treatment: from epidemiologic data to randomized trials and new devices | 7.3 | 0 | Citations (PDF) |
| 152 | Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment | 7.3 | 78 | Citations (PDF) |
| 153 | Prognostic impact of the updated 2018
HFA‐ESC
definition of advanced heart failure: results from the
HELP‐HF
registry | 7.3 | 43 | Citations (PDF) |
| 154 | Distinct pathophysiological pathways in women and men with heart failure | 7.3 | 21 | Citations (PDF) |
| 155 | Left atrial volume index and outcome after transcatheter edge‐to‐edge valve repair for secondary mitral regurgitation | 7.3 | 15 | Citations (PDF) |
| 156 | Combined pre- and post-capillary pulmonary hypertension in left heart disease | 3.3 | 12 | Citations (PDF) |
| 157 | Atrioventricular node ablation and pacing for atrial tachyarrhythmias: A meta-analysis of postoperative outcomes | 2.2 | 15 | Citations (PDF) |
| 158 | Impact of Continuous Flow Left Ventricular Assist Device on Heart Transplant Candidates: A Multi-State Survival Analysis | 2.5 | 3 | Citations (PDF) |
| 159 | Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial | 2.2 | 33 | Citations (PDF) |
| 160 | June 2022 at a glance: prevention, outcomes and treatment | 7.3 | 0 | Citations (PDF) |
| 161 | Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter‐defibrillator for primary prevention? | 7.3 | 25 | Citations (PDF) |
| 162 | Transcatheter Mitral Valve Repair in Patients With Atrial Functional Mitral Regurgitation | 6.1 | 109 | Citations (PDF) |
| 163 | Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study | 1.2 | 7 | Citations (PDF) |
| 164 | Medical therapy for heart failure with preserved ejection fraction: Still a minefield, but with new hope | 0.8 | 0 | Citations (PDF) |
| 165 | July 2022 at a glance: focus on prognosis, devices and valvular heart disease | 7.3 | 0 | Citations (PDF) |
| 166 | Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial | 2.2 | 194 | Citations (PDF) |
| 167 | August 2022 at a glance: focus on heart failure with preserved ejection fraction and cardiac amyloidosis | 7.3 | 1 | Citations (PDF) |
| 168 | Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure? | 2.2 | 36 | Citations (PDF) |
| 169 | Myocarditis Following SARS-CoV2 mRNA Vaccination Against COVID-19 | 2.3 | 5 | Citations (PDF) |
| 170 | Maternal Right Ventricular and Left Atrial Function in Uncomplicated Twin Pregnancies: A Longitudinal Study | 2.5 | 1 | Citations (PDF) |
| 171 | Maternal Left Ventricular Function in Uncomplicated Twin Pregnancies: A Speckle-Tracking Imaging Longitudinal Study | 2.5 | 5 | Citations (PDF) |
| 172 | Pathophysiologic Processes and Novel Biomarkers Associated With Congestion in Heart Failure | 4.4 | 68 | Citations (PDF) |
| 173 | Functional and metabolic frailty predicts mortality in patients undergoing TAVI: Insights from the OBSERVANT II study | 2.7 | 18 | Citations (PDF) |
| 174 | September 2022 at a glance | 7.3 | 0 | Citations (PDF) |
| 175 | Updates in heart failure: sodium glucose co-transporter 2 inhibitors and beyond – major changes are coming | 1.2 | 6 | Citations (PDF) |
| 176 | Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction | 3.3 | 3 | Citations (PDF) |
| 177 | October 2022 at a glance: focus on clinical trials | 7.3 | 0 | Citations (PDF) |
| 178 | Impact and predictors of device-related thrombus after percutaneous left atrial appendage closure | 1.2 | 6 | Citations (PDF) |
| 179 | November 2022 at a glance: focus on epidemiology, prognosis and comorbidities | 7.3 | 1 | Citations (PDF) |
| 180 | 1113 EFFICACY OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION ACROSS DIFFERENT DEFINITIONS: A META-ANALYSIS OF PHASE 3 RANDOMIZED CONTROLLED TRIALS | 0.1 | 0 | Citations (PDF) |
| 181 | Heart Failure: An Update from the Last Years and a Look at the Near Future | 3.1 | 57 | Citations (PDF) |
| 182 | December 2022 at a glance: heart failure with preserved ejection fraction, sodium–glucose cotransporter 2 inhibitors and cardiac amyloidosis | 7.3 | 0 | Citations (PDF) |
| 183 | Heart failure treatment up‐titration and outcome and age: an analysis of BIOSTAT‐CHF | 7.3 | 32 | Citations (PDF) |
| 184 | Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure | 34.5 | 1,656 | Citations (PDF) |
| 185 | Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure | 34.5 | 554 | Citations (PDF) |
| 186 | Effects of a Novel Nitroxyl Donor in Acute Heart Failure | 4.4 | 24 | Citations (PDF) |
| 187 | Is acute heart failure a distinctive disorder? An analysis from
BIOSTAT‐CHF | 7.3 | 23 | Citations (PDF) |
| 188 | Discontinuation and Non-Publication of Heart Failure Randomized Controlled Trials: A Call to Publish All Trial Results | 3.1 | 29 | Citations (PDF) |
| 189 | Renal failure after trans-catheter aortic valve implantation | 2.7 | 2 | Citations (PDF) |
| 190 | Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the
RELAX‐AHF
‐2 study | 7.3 | 13 | Citations (PDF) |
| 191 | Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review | 4.4 | 32 | Citations (PDF) |
| 192 | Thrombotic risk in patients with COVID-19 | 1.1 | 12 | Citations (PDF) |
| 193 | January 2021 at a glance: focus on sex differences, acute heart failure and exercise capacity | 7.3 | 0 | Citations (PDF) |
| 194 | February 2021 at a glance: focus on amyloidosis, myocarditis and cardiomyopathy | 7.3 | 0 | Citations (PDF) |
| 195 | Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure | 0.4 | 7 | Citations (PDF) |
| 196 | Revisiting and Implementing the Weber and Ventilatory Functional Classifications in Heart Failure by Cardiopulmonary Imaging Phenotyping | 4.0 | 19 | Citations (PDF) |
| 197 | Prognostic Value of Pre-operative Atrial Fibrillation in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation | 1.8 | 11 | Citations (PDF) |
| 198 | Adherence and Optimization of Angiotensin Converting Enzyme Inhibitor/Angiotensin II Receptors Blockers and Beta-Blockers in Patients Hospitalized for Acute Heart Failure | 3.1 | 18 | Citations (PDF) |
| 199 | The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC | 2.2 | 133 | Citations (PDF) |
| 200 | March 2021 at a glance: focus on epidemiology, prevention and
COVID
‐19 | 7.3 | 4 | Citations (PDF) |
| 201 | The value of spot urinary creatinine as a marker of muscle wasting in patients with new‐onset or worsening heart failure | 9.1 | 24 | Citations (PDF) |
| 202 | Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure | 7.3 | 1,425 | Citations (PDF) |
| 203 | Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction | 7.3 | 133 | Citations (PDF) |
| 204 | Evidence-Based Management of Acute Heart Failure | 2.6 | 23 | Citations (PDF) |
| 205 | Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire | 7.3 | 50 | Citations (PDF) |
| 206 | Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure | 4.4 | 42 | Citations (PDF) |
| 207 | Myocardial Involvement in COVID-19: an Interaction Between Comorbidities and Heart Failure with Preserved Ejection Fraction. A Further Indication of the Role of Inflammation | 2.9 | 24 | Citations (PDF) |
| 208 | Thromboembolism in Heart Failure Patients in Sinus Rhythm | 4.4 | 35 | Citations (PDF) |
| 209 | April 2021 at a glance: focus on systolic function, quality of life and treatment in heart failure | 7.3 | 0 | Citations (PDF) |
| 210 | Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features | 2.8 | 36 | Citations (PDF) |
| 211 | Impaired High‐Density Lipoprotein Function in Patients With Heart Failure | 4.0 | 24 | Citations (PDF) |
| 212 | Patient profiling in heart failure for tailoring medical therapy. A consensus document of the
Heart Failure Association of the European Society of Cardiology | 7.3 | 251 | Citations (PDF) |
| 213 | FC 021EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY FOLLOWING ACUTE HEART FAILURE, ACCORDING TO BASELINE EGFR: A SUBGROUP ANALYSIS OF THE AFFIRM-AHF TRIAL | 0.8 | 1 | Citations (PDF) |
| 214 | Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment? | 4.0 | 28 | Citations (PDF) |
| 215 | May 2021 at a glance: focus on acute heart failure and heart failure with preserved ejection fraction | 7.3 | 0 | Citations (PDF) |
| 216 | Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure | 2.0 | 5 | Citations (PDF) |
| 217 | Heart failure and pulmonary hypertension in a patient with partial anomalous pulmonary venous return and hyperthyroidism: a case report | 1.2 | 0 | Citations (PDF) |
| 218 | Non‐adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography‐tandem mass spectrometry (results of a prospective multicentre study) | 7.3 | 33 | Citations (PDF) |
| 219 | Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients with New-Onset or Worsening Heart Failure with Reduced and Preserved Ejection Fraction | 3.1 | 81 | Citations (PDF) |
| 220 | Association between up‐titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum | 7.3 | 14 | Citations (PDF) |
| 221 | Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins? | 3.3 | 9 | Citations (PDF) |
| 222 | June 2021 at a glance: focus on epidemiology, biomarkers and medical treatment | 7.3 | 0 | Citations (PDF) |
| 223 | Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy | 1.8 | 29 | Citations (PDF) |
| 224 | July 2021 at a glance: focus on blood volume distribution, haemodynamics and adherence to therapy | 7.3 | 0 | Citations (PDF) |
| 225 | Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study | 2.0 | 43 | Citations (PDF) |
| 226 | Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF | 2.3 | 97 | Citations (PDF) |
| 227 | The Prognostic Value of Serial Troponin Measurements in Patients Admitted for COVID-19 | 3.1 | 35 | Citations (PDF) |
| 228 | Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19 | 2.1 | 7 | Citations (PDF) |
| 229 | SARS-CoV-2, myocardial injury and inflammation: insights from a large clinical and autopsy study | 2.8 | 36 | Citations (PDF) |
| 230 | August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices | 7.3 | 0 | Citations (PDF) |
| 231 | Guidance on the management of left ventricular assist device
(LVAD)
supported patients for the non‐
LVAD
specialist healthcare provider: executive summary | 7.3 | 48 | Citations (PDF) |
| 232 | Sacubitril/Valsartan in Real-Life European Patients with Heart Failure and Reduced Ejection Fraction: A Systematic Review and Meta-Analysis | 3.1 | 38 | Citations (PDF) |
| 233 | Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure | 9.6 | 60 | Citations (PDF) |
| 234 | Impact of mitral regurgitation in patients with worsening heart failure: insights from
BIOSTAT‐CHF | 7.3 | 58 | Citations (PDF) |
| 235 | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure | 2.2 | 11,961 | Citations (PDF) |
| 236 | COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae | 2.4 | 109 | Citations (PDF) |
| 237 | Heart Failure Association of the European Society of Cardiology Position Paper on the Management of Left Ventricular Assist Device-Supported Patients for the Non-Left Ventricular Assist Device Specialist Healthcare Provider: Part 2: At the Emergency Department | 3.1 | 13 | Citations (PDF) |
| 238 | High troponin levels in patients hospitalized for coronavirus disease 2019: a maker or a marker of prognosis? | 1.2 | 5 | Citations (PDF) |
| 239 | HFA of the ESC Position Paper on the Management of LVAD Supported Patients for the Non LVAD Specialist Healthcare Provider Part 1: Introduction and at the Non-Hospital Settings in the Community | 3.1 | 16 | Citations (PDF) |
| 240 | Amended
STRONG‐HF
study design | 7.3 | 15 | Citations (PDF) |
| 241 | September 2021 at a glance: focus on biomarkers, sex differences and adherence to medical treatment | 7.3 | 0 | Citations (PDF) |
| 242 | HFA of the ESC Position Paper on the Management of LVAD-Supported Patients for the Non-LVAD Specialist Healthcare Provider Part 3: At the Hospital and Discharge | 3.1 | 31 | Citations (PDF) |
| 243 | Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure: An Analysis of Individual Patient Data From 4 Randomized Clinical Trials | 4.0 | 14 | Citations (PDF) |
| 244 | Congestion in Patients with Advanced Heart Failure | 1.9 | 17 | Citations (PDF) |
| 245 | The impact of COVID-19 pandemic on AMI and stroke mortality in Lombardy: Evidence from the epicenter of the pandemic | 2.3 | 7 | Citations (PDF) |
| 246 | Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials | 2.9 | 2 | Citations (PDF) |
| 247 | Percutaneous Edge-to-Edge Mitral Valve Repair: Beyond the Left Heart | 3.4 | 12 | Citations (PDF) |
| 248 | COAPT-Like Profile Predicts Long-Term Outcomes in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation | 3.0 | 110 | Citations (PDF) |
| 249 | The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study | 2.2 | 93 | Citations (PDF) |
| 250 | Creatine deficiency and heart failure | 3.3 | 38 | Citations (PDF) |
| 251 | COVID
‐19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology | 7.3 | 51 | Citations (PDF) |
| 252 | Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure | 4.4 | 19 | Citations (PDF) |
| 253 | Antithrombotic and Anticoagulation Therapies in Cardiogenic Shock: A Critical Review of the Published Literature | 3.1 | 24 | Citations (PDF) |
| 254 | October 2021 at a glance: focus on imaging, biomarkers and comorbidities | 7.3 | 0 | Citations (PDF) |
| 255 | Intra-Aortic Balloon Pumping in Acute Decompensated Heart Failure With Hypoperfusion: From Pathophysiology to Clinical Practice | 4.4 | 61 | Citations (PDF) |
| 256 | Unusual intracardiac thrombosis in two patients with coronavirus disease 2019 (COVID-19): case series | 0.5 | 5 | Citations (PDF) |
| 257 | ‘Time is Prognosis’ in Heart Failure: Time-to-Treatment Initiation as a Modifiable Risk Factor | 3.1 | 114 | Citations (PDF) |
| 258 | Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline‐directed medical therapy in heart failure with reduced ejection fraction | 7.3 | 53 | Citations (PDF) |
| 259 | November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices | 7.3 | 0 | Citations (PDF) |
| 260 | 267 Cardiac biomarkers and mortality in COVID-19 infection | 0.1 | 0 | Citations (PDF) |
| 261 | 261 A case of metastatic myxoid liposarcoma causing cardiac tamponade | 0.1 | 0 | Citations (PDF) |
| 262 | 465 Unmasking the prevalence of cardiac amyloidosis in the real world: first insights from the phase 2 of active study, an Italian nationwide survey | 0.1 | 0 | Citations (PDF) |
| 263 | Outcomes Stratified by Adapted Inclusion Criteria After Mitral Edge-to-Edge Repair | 2.3 | 65 | Citations (PDF) |
| 264 | Impact of RAAS Inhibitors on Clinical Outcome and Mortality in Patients With STEMI During the COVID-19 Era: A Multicenter Observational Study | 2.4 | 2 | Citations (PDF) |
| 265 | 132 Clinical characteristics and outcomes of a contemporary, real-world, single-centre cohort of patients with advanced heart failure | 0.1 | 0 | Citations (PDF) |
| 266 | December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models | 7.3 | 0 | Citations (PDF) |
| 267 | A Year in Heart Failure: An Update of Recent Findings | 3.1 | 42 | Citations (PDF) |
| 268 | 484 Echocardiographic patterns in patients with apolipoprotein AI amyloidosis | 0.1 | 0 | Citations (PDF) |
| 269 | 566 Transthyretin and light-chain cardiac amyloidosis: clinical characteristics, echocardiographic findings, and outcomes of a large cohort of patients in Northern Italy | 0.1 | 0 | Citations (PDF) |
| 270 | 278 Cardiac involvement in a 23 years old patient with granulomatosis with polyangiitis (GPA) | 0.1 | 1 | Citations (PDF) |
| 271 | Plasma Proteomic Approach in Patients with Heart Failure: Insights into Pathogenesis of Disease Progression and Potential Novel Treatment Targets | 7.3 | 40 | Citations (PDF) |
| 272 | Concentric vs. Eccentric Remodelling in Heart Failure with Reduced Ejection Fraction: Clinical Characteristics, Pathophysiology and Response to Treatment | 7.3 | 79 | Citations (PDF) |
| 273 | Prognostic value of right ventricular free wall longitudinal strain in a large cohort of outpatients with left-side heart disease | 1.4 | 56 | Citations (PDF) |
| 274 | Genetic Risk and Atrial Fibrillation in Patients with Heart Failure | 7.3 | 27 | Citations (PDF) |
| 275 | Gender and Age Normalization and Ventilation Efficiency During Exercise in Heart Failure with Reduced Ejection Fraction | 3.1 | 29 | Citations (PDF) |
| 276 | Evaluation of Kidney Function Throughout the Heart Failure Trajectory – A Position Statement from the Heart Failure Association of the European Society of Cardiology | 7.3 | 362 | Citations (PDF) |
| 277 | Effects of Serelaxin in Patients Admitted for Acute Heart Failure: A Meta-Analysis | 7.3 | 37 | Citations (PDF) |
| 278 | Clinical Value of Pre-Discharge Bio-Adrenomedullin as a Marker of Residual Congestion and High Risk of Heart Failure Hospital Readmission | 7.3 | 54 | Citations (PDF) |
| 279 | European Society of Cardiology/Heart Failure Association Position Paper on the Role and Safety of New Glucose-Lowering Drugs in Patients with Heart Failure | 7.3 | 152 | Citations (PDF) |
| 280 | Imaging in Patients with Suspected Acute Heart Failure: Timeline Approach Position Statement on Behalf of the Heart Failure Association of the European Society of Cardiology | 7.3 | 67 | Citations (PDF) |
| 281 | Cardiovascular and Non-Cardiovascular Death Distinction: The Utility of Troponin Beyond N-Terminal Pro-B-Type Natriuretic Peptide. Findings from the BIOSTAT-CHF Study | 7.3 | 17 | Citations (PDF) |
| 282 | The Role of Cathepsin D in the Pathophysiology of Heart Failure and its Potentially Beneficial Properties: A Translational Approach | 7.3 | 40 | Citations (PDF) |
| 283 | Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation | 4.4 | 50 | Citations (PDF) |
| 284 | Heart Failure Association of the European Society of Cardiology Update on Sodium–Glucose Co-Transporter 2 Inhibitors in Heart Failure | 7.3 | 77 | Citations (PDF) |
| 285 | July 2020 at a Glance: Focus on Imaging and Cardiomyopathies | 7.3 | 0 | Citations (PDF) |
| 286 | Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction: GALACTIC-HF Baseline Characteristics and Comparison with Contemporary Clinical Trials | 7.3 | 63 | Citations (PDF) |
| 287 | Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure | 2.3 | 98 | Citations (PDF) |
| 288 | MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry | 1.1 | 114 | Citations (PDF) |
| 289 | ACE2 down-regulation may contribute to the increased thrombotic risk in COVID-19 | 2.2 | 12 | Citations (PDF) |
| 290 | Sinus Node Dysfunction in a Young Patient With COVID-19 | 0.5 | 24 | Citations (PDF) |
| 291 | Implications of Serial Measurements of Natriuretic Peptides in Heart Failure: Insights from BIOSTAT-CHF | 7.3 | 11 | Citations (PDF) |
| 292 | Cause of Death in Patients With Acute Heart Failure | 4.4 | 18 | Citations (PDF) |
| 293 | Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial | 62.1 | 663 | Citations (PDF) |
| 294 | Heart Failure in the Last Year: Progress and Perspective | 3.1 | 67 | Citations (PDF) |
| 295 | November 2020 at a Glance: Focus on Comorbidities and Medical Treatment | 7.3 | 1 | Citations (PDF) |
| 296 | Impact of Heart Failure on the Clinical Course and Outcomes of Patients Hospitalized for COVID-19. Results of the Cardio-COVID-Italy Multicentre Study | 7.3 | 124 | Citations (PDF) |
| 297 | Atrial fibrillation in the COVID-19 era: simple bystander or marker of increased risk? | 2.2 | 27 | Citations (PDF) |
| 298 | June 2020 at a Glance: Focus on COVID-19, Quality of Life and Comorbidities | 7.3 | 5 | Citations (PDF) |
| 299 | Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction | 1.2 | 64 | Citations (PDF) |
| 300 | Coronavirus disease 2019 (COVID-19) in the heart transplant population: a single-centre experience | 1.4 | 19 | Citations (PDF) |
| 301 | Elevated Plasma Endothelin-1 is Related to Low Natriuresis, Clinical Signs of Congestion, and Poor Outcome in Acute Heart Failure | 3.1 | 25 | Citations (PDF) |
| 302 | September 2020 at a Glance: Focus on Heart Failure with Preserved Ejection Fraction and Medical Therapy | 7.3 | 0 | Citations (PDF) |
| 303 | Second European Society of Cardiology Cardiac Resynchronization Therapy Survey: the Italian cohort | 1.2 | 1 | Citations (PDF) |
| 304 | August 2020 at a Glance: Focus on Neurohormonal Antagonists and Electrolytes | 7.3 | 0 | Citations (PDF) |
| 305 | A case of combined aortic bioprosthetic valve degeneration and patient–prosthesis mismatch during pregnancy: decision-making and implications after pregnancy | 1.2 | 0 | Citations (PDF) |
| 306 | Coronavirus disease 2019 and cardiovascular implications | 1.2 | 22 | Citations (PDF) |
| 307 | Management of acute coronary syndromes during the COVID-19 outbreak in Lombardy: The “macro-hub” experience | 0.7 | 12 | Citations (PDF) |
| 308 | October 2020 at a Glance: Focus on Outcomes, Valve Disease and Patients’ Monitoring | 7.3 | 0 | Citations (PDF) |
| 309 | Differences in biomarkers and molecular pathways according to age for patients with HFrEF | 5.5 | 8 | Citations (PDF) |
| 310 | Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study | 2.8 | 36 | Citations (PDF) |
| 311 | Guideline-Directed Medical Therapy for Heart Failure does not Exist: A Non-Judgmental Framework for Describing the Level of Adherence to Evidence-Based Drug Treatments for Patients with a Reduced Ejection Fraction | 7.3 | 52 | Citations (PDF) |
| 312 | Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors | 2.2 | 413 | Citations (PDF) |
| 313 | Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy | 2.2 | 485 | Citations (PDF) |
| 314 | The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management | 4.0 | 24 | Citations (PDF) |
| 315 | COVID-19 and Heart Failure: From Infection to Inflammation and Angiotensin II Stimulation. Searching for Evidence from a New Disease | 7.3 | 221 | Citations (PDF) |
| 316 | Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy | 7.1 | 693 | Citations (PDF) |
| 317 | May 2020 at a Glance: Ischaemic Heart Failure and Sex-Related Differences | 7.3 | 3 | Citations (PDF) |
| 318 | Management of Heart Failure Patients with COVID-19: A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology | 7.3 | 109 | Citations (PDF) |
| 319 | Epidemiology, Pathophysiology and Contemporary Management of Cardiogenic Shock – A Position Statement from the Heart Failure Association of the European Society of Cardiology | 7.3 | 463 | Citations (PDF) |
| 320 | Publication Rates of Heart Failure Clinical Trials Remain Low | 2.3 | 11 | Citations (PDF) |
| 321 | Direct oral anticoagulants across the heart failure spectrum: the precision medicine era | 3.3 | 5 | Citations (PDF) |
| 322 | Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) | 2.2 | 71 | Citations (PDF) |
| 323 | Clinical Role of CA125 in Worsening Heart Failure | 4.4 | 103 | Citations (PDF) |
| 324 | The Burden of Non-Cardiac Comorbidities and Association with Clinical Outcomes in an Acute Heart Failure Trial – Insights from ASCEND-HF | 7.3 | 42 | Citations (PDF) |
| 325 | Heart Failure with Mid-Range Ejection Fraction: Pro and Cons of the New Classification of Heart Failure by European Society of Cardiology Guidelines | 3.1 | 45 | Citations (PDF) |
| 326 | March 2020 at a Glance: Heart Failure with Preserved Ejection Fraction, Left Atrial Myopathy, Atrial Fibrillation and Cardiac Amyloidosis | 7.3 | 1 | Citations (PDF) |
| 327 | Life-saving transcatheter aortic valve implantation for acute severe aortic regurgitation due to rheumatoid arthritis and complicated by cardiogenic shock | 1.2 | 2 | Citations (PDF) |
| 328 | Relationship Between Left Ventricular Ejection Fraction and Cardiovascular Outcomes Following Hospitalization for Heart Failure: Insights from the RELAX-AHF-2 Trial | 7.3 | 35 | Citations (PDF) |
| 329 | In-Hospital and Long-Term Mortality for Acute Heart Failure: Analysis at the Time of Admission to the Emergency Department | 3.1 | 52 | Citations (PDF) |
| 330 | Sodium–Glucose Co-Transporter 2 Inhibitors in Heart Failure: Beyond Glycaemic Control. A Position Paper of the Heart Failure Association of the European Society of Cardiology | 7.3 | 117 | Citations (PDF) |
| 331 | February 2020 at a Glance: Acute Heart Failure and Cardio-Oncology | 7.3 | 0 | Citations (PDF) |
| 332 | Distinct Pathological Pathways in Patients With Heart Failure and Diabetes | 4.4 | 34 | Citations (PDF) |
| 333 | Treatment with 24 Hour Istaroxime Infusion in Patients Hospitalised for Acute Heart Failure: A Randomised, Placebo-Controlled Trial | 7.3 | 61 | Citations (PDF) |
| 334 | Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study | 2.8 | 15 | Citations (PDF) |
| 335 | January 2020 at a Glance: Translational Medicine, Predictors of Outcome and Treatments | 7.3 | 5 | Citations (PDF) |
| 336 | Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction | 4.4 | 135 | Citations (PDF) |
| 337 | April 2020 at a Glance: Epidemiology, Prevention, and Biomarkers | 7.3 | 0 | Citations (PDF) |
| 338 | Acute Coronary Syndromes and Acute Heart Failure: A Diagnostic Dilemma and High-Risk Combination. A Statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology | 7.3 | 85 | Citations (PDF) |
| 339 | Association Between Loop Diuretic Dose Changes and Outcomes in Chronic Heart Failure: Observations from the ESC-EORP Heart Failure Long-Term Registry | 7.3 | 62 | Citations (PDF) |
| 340 | A Network Analysis to Identify Pathophysiological Pathways Distinguishing Ischaemic from Non-Ischaemic Heart Failure | 7.3 | 36 | Citations (PDF) |
| 341 | Acute heart failure: More questions than answers | 5.6 | 55 | Citations (PDF) |
| 342 | Mega-Trials in Heart Failure: Effects of Dilution in Examination of New Therapies | 7.3 | 12 | Citations (PDF) |
| 343 | Drug development in oncology and devices—lessons for heart failure drug development and approval? a review | 3.3 | 0 | Citations (PDF) |
| 344 | Maternal hemodynamics, arterial stiffness and elastic aortic properties in twin pregnancy | 2.6 | 6 | Citations (PDF) |
| 345 | Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction | 2.8 | 29 | Citations (PDF) |
| 346 | Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test | 1.8 | 12 | Citations (PDF) |
| 347 | December 2020 at a Glance: Focus on COVID-19, Comorbidities and Palliative Care | 7.3 | 2 | Citations (PDF) |
| 348 | Left Ventricular Reverse Remodelling Predicts Long-Term Outcomes in Patients with Functional Mitral Regurgitation Undergoing Mitraclip Therapy: Results from a Multicentre Registry | 7.3 | 62 | Citations (PDF) |
| 349 | Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP and GDF-15, of Heart Failure Therapies (STRONG-HF): Rationale and Design for a Multicentre, Randomized, Parallel-Group Study | 7.3 | 59 | Citations (PDF) |
| 350 | August 2019 at a Glance: Arrhythmogenic Cardiomyopathy, Biomarkers of Inflammation, Insulin Treatment, Initiation of Sacubitril/Valsartan, and Pharmacy-Based Intervention to Increase Medication Adherence | 7.3 | 0 | Citations (PDF) |
| 351 | Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying ApproachDrugs, 2019, 79, 1543-1556 | 11.4 | 16 | Citations (PDF) |
| 352 | Cardiac Implantable Electronic Devices with a Defibrillator Component and All-Cause Mortality in Left Ventricular Assist Device Carriers: Results from the PCHF-VAD Registry | 7.3 | 39 | Citations (PDF) |
| 353 | Effects of Serelaxin in Patients with Acute Heart Failure | 34.5 | 250 | Citations (PDF) |
| 354 | Trajectories of Changes in Renal Function in Patients with Acute Heart Failure | 1.8 | 20 | Citations (PDF) |
| 355 | July 2019 at a Glance: Imaging of Congestion, Sodium–Glucose Co-Transporter 2 Inhibitors, Myocardial Function and Mitraclip Trials | 7.3 | 1 | Citations (PDF) |
| 356 | Geographical Location Affects the Levels and Association of Trimethylamine N-Oxide with Heart Failure Mortality in BIOSTAT-CHF: A Post-Hoc Analysis | 7.3 | 33 | Citations (PDF) |
| 357 | Hepatorenal Dysfunction Identifies High-Risk Patients with Acute Heart Failure: Insights from the RELAX-AHF Trial | 3.1 | 31 | Citations (PDF) |
| 358 | Is Plasma Renin Activity Associated with Worse Outcomes in Acute Heart Failure? A Secondary Analysis from the BLAST-AHF Trial | 7.3 | 12 | Citations (PDF) |
| 359 | Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality | 4.4 | 38 | Citations (PDF) |
| 360 | September 2019 at a Glance: Focus on Devices | 7.3 | 0 | Citations (PDF) |
| 361 | October 2019 at a Glance: Epidemiology, Prevention, and Modes of Death | 7.3 | 0 | Citations (PDF) |
| 362 | Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study | 62.1 | 223 | Citations (PDF) |
| 363 | Treatment of Functional Mitral Regurgitation in Chronic Heart Failure: Can We Get A ‘Proof of Concept’ from the MITRA-FR and COAPT TRIALS? | 7.3 | 100 | Citations (PDF) |
| 364 | Clinical Practice Update on Heart Failure 2019: Pharmacotherapy, Procedures, Devices and Patient Management. An Expert Consensus Meeting Report of the Heart Failure Association of the European Society of Cardiology | 7.3 | 551 | Citations (PDF) |
| 365 | Expert Consensus Document: Reporting Checklist for Quantification of Pulmonary Congestion by Lung Ultrasound in Heart Failure | 7.3 | 122 | Citations (PDF) |
| 366 | June 2019 at a Glance: From Genetics to Haemodynamics, Biomarkers and Imaging for the Prediction of Outcomes | 7.3 | 0 | Citations (PDF) |
| 367 | Heart Failure Association of the European Society of Cardiology Practical Guidance on the Use of Natriuretic Peptide Concentrations | 7.3 | 712 | Citations (PDF) |
| 368 | Elastic aortic properties in cystic fibrosis adults without cardiovascular risk factors: A case‐control study | 0.9 | 14 | Citations (PDF) |
| 369 | May 2019 at a Glance: Epidemiology, Drug Effects On Biomarkers, Adverse Events With LVAD | 7.3 | 0 | Citations (PDF) |
| 370 | Focus on echocardiographic right ventricular strain analysis in cystic fibrosis adults without cardiovascular risk factors: a case–control study | 2.6 | 9 | Citations (PDF) |
| 371 | The Clinical Significance of Interleukin-6 in Heart Failure: Results from the BIOSTAT-CHF Study | 7.3 | 268 | Citations (PDF) |
| 372 | Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure | 4.4 | 41 | Citations (PDF) |
| 373 | Heart Failure in Cardiomyopathies: A Position Paper from the Heart Failure Association of the European Society of Cardiology | 7.3 | 339 | Citations (PDF) |
| 374 | Clinical Profiles in Acute Heart Failure: An Urgent Need for a New Approach | 3.1 | 50 | Citations (PDF) |
| 375 | March 2019 at a Glance: Epidemiology and Clinical Trials | 7.3 | 0 | Citations (PDF) |
| 376 | Bio-Adrenomedullin as a Marker of Congestion in Patients with New-Onset and Worsening Heart Failure | 7.3 | 96 | Citations (PDF) |
| 377 | The Role of Ventricular–Arterial Coupling in Cardiac Disease and Heart Failure: Assessment, Clinical Implications and Therapeutic Interventions. A Consensus Document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association | 7.3 | 355 | Citations (PDF) |
| 378 | April 2019 at a Glance: Prediction of Heart Failure, Left Atrial Function, Cardio-Oncology | 7.3 | 0 | Citations (PDF) |
| 379 | Prognostic Implications of Changes in Amino-Terminal Pro–B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF | 1.8 | 12 | Citations (PDF) |
| 380 | Serial Assessment of Spot Urine Sodium Predicts Effectiveness of Decongestion and Outcome in Patients with Acute Heart Failure | 7.3 | 104 | Citations (PDF) |
| 381 | February 2019 At a Glance: Pathophysiology, Exercise Capacity, Diuretics and Valve Disease | 7.3 | 1 | Citations (PDF) |
| 382 | Highlights in Heart Failure | 3.1 | 197 | Citations (PDF) |
| 383 | The potential antiarrhythmic properties of sacubitril/valsartan: a case report | 1.2 | 2 | Citations (PDF) |
| 384 | November 2019 at a Glance. Chronic and Acute Heart Failure: From Epidemiology to Treatment | 7.3 | 2 | Citations (PDF) |
| 385 | December 2019 at a Glance: Economic Burden, Co-Morbidities, and Prognosis | 7.3 | 1 | Citations (PDF) |
| 386 | Rationale and Design of the AFFIRM-AHF Trial: A Randomised, Double-Blind, Placebo-Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron-Deficient Patients Admitted for Acute Heart Failure | 7.3 | 49 | Citations (PDF) |
| 387 | Exercise Oscillatory Ventilation and Prognosis in Heart Failure Patients with Reduced and Mid-Range Ejection Fraction | 7.3 | 30 | Citations (PDF) |
| 388 | Elastic properties of ascending aorta and ventricular–arterial coupling in women with previous pregnancy complicated by HELLP syndrome | 2.1 | 14 | Citations (PDF) |
| 389 | Adrenomedullin in Heart Failure: Pathophysiology and Therapeutic Application | 7.3 | 205 | Citations (PDF) |
| 390 | The Use of Diuretics in Heart Failure with Congestion — A Position Statement from the Heart Failure Association of the European Society of Cardiology | 7.3 | 997 | Citations (PDF) |
| 391 | Clinical Correlates and Outcome Associated with Changes in 6-Minute Walking Distance in Patients with Heart Failure: Findings from the BIOSTAT-CHF Study | 7.3 | 44 | Citations (PDF) |
| 392 | Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation | 2.8 | 12 | Citations (PDF) |
| 393 | Heart Failure Prognosis Over Time: How the Prognostic Role of Oxygen Consumption and Ventilatory Efficiency During Exercise has Changed in the Last 20 Years | 7.3 | 75 | Citations (PDF) |
| 394 | January 2019 at a Glance: Prognostic Assessment, Left Ventricular Assist Devices, Disease Management and Quality of Care | 7.3 | 4 | Citations (PDF) |
| 395 | Endomyocardial fibrosis and myocardial infarction leading to diastolic and systolic dysfunction requiring transplantation | 1.5 | 3 | Citations (PDF) |
| 396 | Association with Outcomes and Response to Treatment of Trimethylamine N-Oxide in Heart Failure: Results from BIOSTAT-CHF | 7.3 | 96 | Citations (PDF) |
| 397 | Heart Failure in the Outpatient Versus Inpatient Setting: Findings from the BIOSTAT-CHF Study | 7.3 | 56 | Citations (PDF) |
| 398 | Treatments targeting inotropy | 2.2 | 193 | Citations (PDF) |
| 399 | The myth of ‘stable’ coronary artery disease | 35.5 | 138 | Citations (PDF) |
| 400 | The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure | 2.8 | 43 | Citations (PDF) |
| 401 | Systemic Lupus Erythematosus and Endothelial Dysfunction: A Close Relationship | 1.3 | 33 | Citations (PDF) |
| 402 | The role of type 2 diabetes mellitus on hypertensive‐related aortic stiffness | 0.9 | 11 | Citations (PDF) |
| 403 | Effects of ivabradine on endothelial function, aortic properties and ventricular‐arterial coupling in chronic systolic heart failure patients | 5.3 | 13 | Citations (PDF) |
| 404 | Redefining biomarkers in heart failure | 3.3 | 24 | Citations (PDF) |
| 405 | February 2018 at a Glance: Heart and Brain Interaction, Prognostic Variables, and Acute Heart Failure and Post-Discharge Outcomes | 7.3 | 0 | Citations (PDF) |
| 406 | Mineralocorticoid Receptor Antagonists for Heart Failure: A Real-Life Observational Study | 3.1 | 16 | Citations (PDF) |
| 407 | April 2018 at a Glance: Focus on Prognostic Variables | 7.3 | 0 | Citations (PDF) |
| 408 | March 2018 at a Glance: Clinical Trials, Co-Morbidities and Treatment of Mitral Regurgitation | 7.3 | 0 | Citations (PDF) |
| 409 | Evaluation of an Individualized Dose Titration Regimen of Patiromer to Prevent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease | 3.1 | 54 | Citations (PDF) |
| 410 | January 2018 at a Glance: Biomarkers, Co-Morbidities and Mechanical Circulatory Support | 7.3 | 0 | Citations (PDF) |
| 411 | Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure | 2.3 | 41 | Citations (PDF) |
| 412 | Proportional pulse pressure relates to cardiac index in stabilized acute heart failure patients | 3.1 | 6 | Citations (PDF) |
| 413 | Proteomic Diversity of High-Density Lipoprotein Explains its Association with Clinical Outcome in Patients with Heart Failure | 7.3 | 34 | Citations (PDF) |
| 414 | Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure | 2.2 | 40 | Citations (PDF) |
| 415 | Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF | 2.2 | 2 | Citations (PDF) |
| 416 | Potassium and the Use of Renin–Angiotensin–Aldosterone System Inhibitors in Heart Failure with Reduced Ejection Fraction: Data from BIOSTAT-CHF | 7.3 | 67 | Citations (PDF) |
| 417 | Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure | 2.2 | 63 | Citations (PDF) |
| 418 | Negotiating renal dysfunction when treating patients with heart failure | 1.8 | 8 | Citations (PDF) |
| 419 | Educational needs and application of guidelines in the management of patients with mitral regurgitation. A European mixed-methods study | 2.2 | 52 | Citations (PDF) |
| 420 | May 2018 at a Glance: The Central Role of Co-Morbidities | 7.3 | 0 | Citations (PDF) |
| 421 | Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure | 4.4 | 6 | Citations (PDF) |
| 422 | Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence | 4.3 | 38 | Citations (PDF) |
| 423 | Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure | 2.2 | 266 | Citations (PDF) |
| 424 | Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality | 18.0 | 160 | Citations (PDF) |
| 425 | Multiparametric Prognostic Scores in Chronic Heart Failure with Reduced Ejection Fraction: A Long-Term Comparison | 7.3 | 99 | Citations (PDF) |
| 426 | Systolic Blood Pressure Reduction During the First 24 H in Acute Heart Failure Admission: Friend or Foe? | 7.3 | 22 | Citations (PDF) |
| 427 | Role of Cardiopulmonary Exercise Testing in Clinical Stratification in Heart Failure. A Position Paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology | 7.3 | 215 | Citations (PDF) |
| 428 | Aetiology, Timing and Clinical Predictors of Early vs. Late Readmission Following Index Hospitalization for Acute Heart Failure: Insights from ASCEND-HF | 7.3 | 57 | Citations (PDF) |
| 429 | P4233Safe multidisciplinary management of new therapies: the RITMO project (Real Time Continuous Web Monitoring) | 2.2 | 0 | Citations (PDF) |
| 430 | Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure | 2.8 | 9 | Citations (PDF) |
| 431 | November 2018 at a Glance: From Prediction of Heart Failure in Asymptomatic Subjects to Advanced Chronic Heart Failure | 7.3 | 1 | Citations (PDF) |
| 432 | December 2018 at a Glance: New Imaging Methods, Translational Cardiology and Non-Medical Treatment | 7.3 | 0 | Citations (PDF) |
| 433 | Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial | 1.8 | 10 | Citations (PDF) |
| 434 | Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points | 4.1 | 18 | Citations (PDF) |
| 435 | October 2018 at a Glance: From Demographic Variables to Genotype–Phenotype Interactions | 7.3 | 0 | Citations (PDF) |
| 436 | Sacubitril/valsartan: from a large clinical trial to clinical practice | 1.2 | 8 | Citations (PDF) |
| 437 | September 2018 at a Glance: Co-Morbidities, Heart Failure with Preserved Ejection Fraction and Mineralocorticoid Receptor Antagonists | 7.3 | 2 | Citations (PDF) |
| 438 | Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects | 4.3 | 25 | Citations (PDF) |
| 439 | Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction | 2.2 | 192 | Citations (PDF) |
| 440 | Advanced Heart Failure: A Position Statement of the Heart Failure Association of the European Society of Cardiology | 7.3 | 783 | Citations (PDF) |
| 441 | Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis | 18.0 | 410 | Citations (PDF) |
| 442 | Prognostic evaluation of the elastic properties of the ascending aorta in dilated cardiomyopathy | 3.0 | 7 | Citations (PDF) |
| 443 | July 2018 at a Glance: Practical Guidance in Acute Heart Failure, Pathophysiology and Clinical Trials of Medical Therapy | 7.3 | 0 | Citations (PDF) |
| 444 | Waist-To-Hip Ratio and Mortality in Heart Failure | 7.3 | 113 | Citations (PDF) |
| 445 | Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation | 2.2 | 16 | Citations (PDF) |
| 446 | Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion | 4.4 | 83 | Citations (PDF) |
| 447 | August 2018 at a Glance: Patients' Outcomes, Obesity and Medical Therapy | 7.3 | 1 | Citations (PDF) |
| 448 | Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction | 2.3 | 288 | Citations (PDF) |
| 449 | Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction | 2.2 | 57 | Citations (PDF) |
| 450 | June 2018 at a Glance: Peripartum Cardiomyopathy and Pathophysiology, Prognosis, and Device Therapy of Heart Failure | 7.3 | 3 | Citations (PDF) |
| 451 | Inappropriate left ventricular mass after preeclampsia: another piece of the puzzle Inappropriate LVM and PE | 3.0 | 12 | Citations (PDF) |
| 452 | Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial | 2.2 | 159 | Citations (PDF) |
| 453 | Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure | 4.4 | 14 | Citations (PDF) |
| 454 | A Multimarker Multi-Time Point-Based Risk Stratification Strategy in Acute Heart Failure: Results from the RELAX-AHF Trial | 7.3 | 96 | Citations (PDF) |
| 455 | January 2017 at a Glance: Oncology, Diabetes and Antidiabetic Treatment, Pulmonary Hypertension | 7.3 | 3 | Citations (PDF) |
| 456 | Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial | 2.8 | 9 | Citations (PDF) |
| 457 | Measurement of Troponin and Natriuretic Peptides Shortly After Admission in Patients with Heart Failure—Does it Add Useful Prognostic Information? an Analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies (VERITAS) | 7.3 | 31 | Citations (PDF) |
| 458 | Prognostic Role of β-Blocker Selectivity and Dosage Regimens in Heart Failure Patients. Insights from the MECKI Score Database | 7.3 | 32 | Citations (PDF) |
| 459 | Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failureHeart, 2017, 103, 407-413 | 3.9 | 104 | Citations (PDF) |
| 460 | Development and Validation of Multivariable Models to Predict Mortality and Hospitalization in Patients with Heart Failure | 7.3 | 226 | Citations (PDF) |
| 461 | Plasma Biomarkers to Predict or Rule Out Early Post-Discharge Events after Hospitalization gor Acute Heart Failure | 7.3 | 38 | Citations (PDF) |
| 462 | March 2017 at a Glance: Pathophysiology, Imaging, Biomarkers and Devices | 7.3 | 0 | Citations (PDF) |
| 463 | Percutaneous edge-to-edge mitral valve repair for the treatment of acute mitral regurgitation complicating myocardial infarction: A single centre experience | 2.2 | 53 | Citations (PDF) |
| 464 | Serelaxin in Addition to Standard Therapy in Acute Heart Failure: Rationale and Design of the RELAX-AHF-2 Study | 7.3 | 117 | Citations (PDF) |
| 465 | Effect of Ivabradine in Patients with Heart Failure with Preserved Ejection Fraction: The Edify Randomized Placebo-Controlled Trial | 7.3 | 188 | Citations (PDF) |
| 466 | Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF) | 2.2 | 140 | Citations (PDF) |
| 467 | Arrhythmias and cardiomyopathy | 1.2 | 3 | Citations (PDF) |
| 468 | Heart failure | 62.1 | 620 | Citations (PDF) |
| 469 | Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction | 4.4 | 101 | Citations (PDF) |
| 470 | Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure | 2.3 | 86 | Citations (PDF) |
| 471 | June 2017 at a Glance: Biomarkers and Medical Treatment | 7.3 | 0 | Citations (PDF) |
| 472 | Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial | 2.9 | 11 | Citations (PDF) |
| 473 | Benefit of Cardiopoietic Mesenchymal Stem Cell Therapy on Left Ventricular Remodelling: Results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) Study | 7.3 | 107 | Citations (PDF) |
| 474 | April 2017 at a Glance: Cardiomyopathies and Clinical Trials | 7.3 | 0 | Citations (PDF) |
| 475 | Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial | 2.9 | 10 | Citations (PDF) |
| 476 | New Medicinal Products for Chronic Heart Failure: Advances in Clinical Trial Design and Efficacy Assessment | 7.3 | 18 | Citations (PDF) |
| 477 | February 2017 at a Glance: Fibrosis, Acute Heart Failure and Neurologic Abnormalities | 7.3 | 2 | Citations (PDF) |
| 478 | Reassessing Phase II Heart Failure Clinical Trials | 4.4 | 15 | Citations (PDF) |
| 479 | October 2017 at a Glance: Phenotyping Heart Failure, Co-Morbidities, Use of Evidence-Based Therapy and New Treatments | 7.3 | 3 | Citations (PDF) |
| 480 | The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure | 2.3 | 57 | Citations (PDF) |
| 481 | September 2017 At A Glance: Epidemiology, Prognosis, Mediterranean Diet and Different Viewpoints on Aspirin | 7.3 | 1 | Citations (PDF) |
| 482 | July 2017 at a Glance: Clinical Assessment, Biomarkers, Cardiac Imaging and Treatment | 7.3 | 0 | Citations (PDF) |
| 483 | Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock | 1.8 | 33 | Citations (PDF) |
| 484 | Prognostic value of the absolute lymphocyte count in patients admitted for acute heart failure | 1.2 | 22 | Citations (PDF) |
| 485 | August 2017 at a Glance: Tailored Treatment, Acute Heart Failure and Cardiac Resynchronization | 7.3 | 1 | Citations (PDF) |
| 486 | November 2017 At a Glance: Quality of Care and Disease Management | 7.3 | 1 | Citations (PDF) |
| 487 | A Network Analysis to Compare Biomarker Profiles in Patients with and without Diabetes Mellitus in Acute Heart Failure | 7.3 | 59 | Citations (PDF) |
| 488 | Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency | 18.0 | 379 | Citations (PDF) |
| 489 | Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial | 2.1 | 9 | Citations (PDF) |
| 490 | Heart failure 2016: still more questions than answers | 2.2 | 23 | Citations (PDF) |
| 491 | Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure | 1.8 | 41 | Citations (PDF) |
| 492 | Heart failure and anemia: Effects on prognostic variables | 2.7 | 44 | Citations (PDF) |
| 493 | Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials) | 1.8 | 52 | Citations (PDF) |
| 494 | Insufficient Reduction in Heart Rate During Hospitalization Despite Beta-Blocker Treatment in Acute Decompensated Heart Failure: Insights from the ASCEND-HF Trial | 7.3 | 22 | Citations (PDF) |
| 495 | ANMCO/SIC Consensus Document: cardiology networks for outpatient heart failure care | 0.1 | 14 | Citations (PDF) |
| 496 | December 2017 at a Glance: Left Ventricular Ejection Fraction, Exercise Capacity, Peripartum Cardiomyopathy | 7.3 | 1 | Citations (PDF) |
| 497 | Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure | 4.4 | 19 | Citations (PDF) |
| 498 | Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF | 2.8 | 40 | Citations (PDF) |
| 499 | Mineralocorticoid Receptor Antagonist Pattern of Use in Heart Failure with Reduced Ejection Fraction: Findings from BIOSTAT-CHF | 7.3 | 95 | Citations (PDF) |
| 500 | Nutritional Deficiency in Patients with Heart Failure | 4.4 | 80 | Citations (PDF) |
| 501 | Nutrition and Cardiovascular Disease: Finding the Perfect Recipe for Cardiovascular Health | 4.4 | 113 | Citations (PDF) |
| 502 | February 2016 at a Glance. Focus Issue on Cardiac Regeneration, Medical Treatment and Cardiac Devices | 7.3 | 0 | Citations (PDF) |
| 503 | European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-Year Follow-Up Outcomes and Differences Across Regions | 7.3 | 739 | Citations (PDF) |
| 504 | Signature of Circulating microRNAs in Patients with Acute Heart Failure | 7.3 | 185 | Citations (PDF) |
| 505 | The Clinical Course of Health Status and Association with Outcomes in Patients Hospitalized for Heart Failure: Insights from ASCEND-HF | 7.3 | 49 | Citations (PDF) |
| 506 | Optimizing Clinical Use of Biomarkers in High-Risk Acute Heart Failure Patients | 7.3 | 76 | Citations (PDF) |
| 507 | March 2016 at a Glance. Focus on Right Ventricular Failure and Acute Heart Failure | 7.3 | 0 | Citations (PDF) |
| 508 | Mitraclip Therapy in Patients with Functional Mitral Regurgitation and Missing Leaflet Coaptation: Is it Still an Exclusion Criterion? | 7.3 | 17 | Citations (PDF) |
| 509 | Exercise Tolerance can Explain the Obesity Paradox in Patients with Systolic Heart Failure: Data from the MECKI Score Research Group | 7.3 | 80 | Citations (PDF) |
| 510 | Targeting N-Terminal Pro-Brain Natriuretic Peptide in Older Versus Younger Acute Decompensated Heart Failure Patients | 4.4 | 13 | Citations (PDF) |
| 511 | Liver Function Tests in Patients with Acute Heart Failure and Associated Outcomes: Insights from ASCEND-HF | 7.3 | 62 | Citations (PDF) |
| 512 | June 2016 at a Glance: Epidemiology, Renal Impairment, Heart Failure with Preserved Ejection Fraction | 7.3 | 1 | Citations (PDF) |
| 513 | Nesiritide in Patients Hospitalized for Acute Heart Failure: Does Timing Matter? Implication for Future Acute Heart Failure Trials | 7.3 | 14 | Citations (PDF) |
| 514 | Abnormal Liver Function Tests in Acute Heart Failure: Relationship with Clinical Characteristics and Outcome in the PROTECT Study | 7.3 | 95 | Citations (PDF) |
| 515 | April 2016 at a Glance. Focus on Cardiac Remodeling, Biomarkers and Treatment | 7.3 | 1 | Citations (PDF) |
| 516 | Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial | 62.1 | 273 | Citations (PDF) |
| 517 | December 2016 at a Glance: Cardiac Metabolism, Myocarditis, Right Ventricular Function and Prognostic Markers | 7.3 | 0 | Citations (PDF) |
| 518 | N-terminal pro-B-type natriuretic peptide-guided therapy in patients hospitalized for acute heart failure | 1.2 | 24 | Citations (PDF) |
| 519 | Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes | 4.4 | 52 | Citations (PDF) |
| 520 | Different types of tricuspid flail: Case reports and review of the literature | 1.7 | 8 | Citations (PDF) |
| 521 | Management of acute heart failure in elderly patients | 1.5 | 38 | Citations (PDF) |
| 522 | Ascending Aortic Dimensions in Hypertensive Subjects: Reference Values for Two-Dimensional Echocardiography | 3.4 | 30 | Citations (PDF) |
| 523 | Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure — Post-hoc analysis of the PROTECT trial | 2.2 | 7 | Citations (PDF) |
| 524 | September 2016 at a Glance: Pregnancy, Hypertrophic Cardiomyopathy, Epidemiology, Medical Treatment | 7.3 | 5 | Citations (PDF) |
| 525 | July 2016 at a Glance: The Critical Role of Co-Morbidities | 7.3 | 3 | Citations (PDF) |
| 526 | Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points | 4.4 | 20 | Citations (PDF) |
| 527 | Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure | 2.2 | 57 | Citations (PDF) |
| 528 | Acute heart failure in the young: Clinical characteristics and biomarker profiles | 2.2 | 15 | Citations (PDF) |
| 529 | August 2016 at a Glance: The New Esc Guidelines, and Pathophysiology, Epidemiology and Prognosis of Heart Failure | 7.3 | 3 | Citations (PDF) |
| 530 | Efficacy and Safety of Edoxaban Compared with Warfarin in Patients with Atrial Fibrillation and Heart Failure: Insights from ENGAGE AF-TIMI 48 | 7.3 | 79 | Citations (PDF) |
| 531 | Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper | 2.2 | 125 | Citations (PDF) |
| 532 | Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure | 4.4 | 134 | Citations (PDF) |
| 533 | Plasma Kidney Injury Molecule-1 in Heart Failure: Renal Mechanisms and Clinical Outcome | 7.3 | 42 | Citations (PDF) |
| 534 | Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) Trial Design | 7.3 | 83 | Citations (PDF) |
| 535 | Increased Mortality with Elevated Plasma Endothelin-1 in Acute Heart Failure: An ASCEND-HF Biomarker Substudy | 7.3 | 62 | Citations (PDF) |
| 536 | A New Format for the Journal and a Farewell | 7.3 | 0 | Citations (PDF) |
| 537 | Cardiorenal Interactions | 1.9 | 12 | Citations (PDF) |
| 538 | In-hospital worsening heart failure in patients admitted for acute heart failure | 2.2 | 17 | Citations (PDF) |
| 539 | November 2016 at a Glance: The Left Atrium, Screening for Heart Failure, Multimodality Imaging for Cardiac Resynchronization Therapy | 7.3 | 0 | Citations (PDF) |
| 540 | October 2016 at a Glance: Treatment of Heart Failure | 7.3 | 0 | Citations (PDF) |
| 541 | A Systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: Rationale, Design, and Baseline Characteristics of BIOSTAT-CHF | 7.3 | 189 | Citations (PDF) |
| 542 | Patient Journey After Admission for Acute Heart Failure: Length Of Stay, 30-Day Readmission and 90-Day Mortality | 7.3 | 60 | Citations (PDF) |
| 543 | May 2016 at a Glance | 7.3 | 0 | Citations (PDF) |
| 544 | Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial) | 1.8 | 29 | Citations (PDF) |
| 545 | Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure | 4.4 | 38 | Citations (PDF) |
| 546 | Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact? | 1.0 | 37 | Citations (PDF) |
| 547 | Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure | 4.4 | 52 | Citations (PDF) |
| 548 | Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial) | 1.8 | 57 | Citations (PDF) |
| 549 | Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients | 2.2 | 36 | Citations (PDF) |
| 550 | Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure | 2.3 | 220 | Citations (PDF) |
| 551 | Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF | 2.8 | 16 | Citations (PDF) |
| 552 | Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias | 2.6 | 22 | Citations (PDF) |
| 553 | Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow? | 1.8 | 148 | Citations (PDF) |
| 554 | The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study | 2.2 | 40 | Citations (PDF) |
| 555 | Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS | 1.8 | 32 | Citations (PDF) |
| 556 | MicroRNAs relate to early worsening of renal function in patients with acute heart failure | 2.2 | 39 | Citations (PDF) |
| 557 | Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study | 2.8 | 21 | Citations (PDF) |
| 558 | Coronary artery disease and high altitude: Unresolved issues | 0.1 | 6 | Citations (PDF) |
| 559 | Recommendations on Pre-Hospital & Early Hospital Management of Acute Heart Failure: A Consensus Paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine | 7.3 | 372 | Citations (PDF) |
| 560 | June 2015 at a Glance | 7.3 | 1 | Citations (PDF) |
| 561 | Exercise Performance Is a Prognostic Indicator in Elderly Patients With Chronic Heart Failure – Application of Metabolic Exercise Cardiac Kidney Indexes Score – | 1.7 | 26 | Citations (PDF) |
| 562 | Renal Function and Peak Exercise Oxygen Consumption in Chronic Heart Failure With Reduced Left Ventricular Ejection Fraction | 1.7 | 33 | Citations (PDF) |
| 563 | July 2015 at a Glance | 7.3 | 0 | Citations (PDF) |
| 564 | Growth Differentiation Factor 15 (GDF-15) in Patients Admitted for Acute Heart Failure: Results from the RELAX-AHF Study | 7.3 | 109 | Citations (PDF) |
| 565 | September 2015 at a Glance | 7.3 | 0 | Citations (PDF) |
| 566 | November 2015 at a Glance | 7.3 | 0 | Citations (PDF) |
| 567 | December 2015 at a Glance | 7.3 | 0 | Citations (PDF) |
| 568 | Echocardiographic evaluation in subjects with α1‐Antitrypsin deficiency | 3.0 | 12 | Citations (PDF) |
| 569 | Endpoints in stem cell trials in ischemic heart failure | 6.6 | 17 | Citations (PDF) |
| 570 | Serial High Sensitivity Cardiac Troponin T Measurement in Acute Heart Failure: Insights from the Relax-Ahf Study | 7.3 | 126 | Citations (PDF) |
| 571 | October 2015 at a glance | 7.3 | 0 | Citations (PDF) |
| 572 | August 2015 at a Glance | 7.3 | 0 | Citations (PDF) |
| 573 | Prognostic value of RV isovolumic acceleration and tissue strain in moderate HFrEF | 3.0 | 11 | Citations (PDF) |
| 574 | Early vs. Late Worsening Heart Failure During Acute Heart Failure Hospitalization: Insights from the PROTECT Trial | 7.3 | 28 | Citations (PDF) |
| 575 | In-Hospital Worsening Heart Failure | 7.3 | 69 | Citations (PDF) |
| 576 | Agents with Vasodilator Properties in Acute Heart Failure: How to Design Successful Trials | 7.3 | 24 | Citations (PDF) |
| 577 | Challenging the Two Concepts in Determining the Appropriate Pre-Discharge N-Terminal Pro-Brain Natriuretic Peptide Treatment Target in Acute Decompensated Heart Failure Patients: Absolute or Relative Discharge Levels? | 7.3 | 42 | Citations (PDF) |
| 578 | The effect of aldosterone-antagonist therapy on aortic elastic properties in patients with nonischemic dilated cardiomyopathy | 1.2 | 22 | Citations (PDF) |
| 579 | Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version | 2.2 | 134 | Citations (PDF) |
| 580 | Characteristics and mid-term follow-up of a single-center population affected by Tako-Tsubo cardiomyopathy | 1.2 | 5 | Citations (PDF) |
| 581 | Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group | 2.7 | 16 | Citations (PDF) |
| 582 | Comparative Effectiveness of Torsemide Versus Furosemide in Heart Failure Patients: Insights From the Protect Trial | 1.0 | 31 | Citations (PDF) |
| 583 | Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms | 2.8 | 17 | Citations (PDF) |
| 584 | Comparative Assessment of Short-Term Adverse Events in Acute Heart Failure With Cystatin C and Other Estimates of Renal Function | 4.4 | 37 | Citations (PDF) |
| 585 | Acute Heart Failure in the Elderly: Differences in Clinical Characteristics, Outcomes, and Prognostic Factors in the VERITAS Study | 1.8 | 79 | Citations (PDF) |
| 586 | Acute Heart Failure in Elderly Patients: Worse Outcomes and Differential Utility of Standard Prognostic Variables. Insights from the PROTECT Trial | 7.3 | 51 | Citations (PDF) |
| 587 | Heart Failure Therapeutics on the Basis of a Biased Ligand of the Angiotensin-2 Type 1 Receptor | 4.4 | 72 | Citations (PDF) |
| 588 | Quantitative Analysis of Right Ventricular (RV) Function With Echocardiography in Chronic Heart Failure With No or Mild RV Dysfunction | 1.8 | 38 | Citations (PDF) |
| 589 | Echocardiographic Evaluation of Aortic Atheromas in Patients With Aortic Stenosis | 1.8 | 1 | Citations (PDF) |
| 590 | April 2015 at a Glance | 7.3 | 1 | Citations (PDF) |
| 591 | March 2015 at a Glance | 7.3 | 0 | Citations (PDF) |
| 592 | May 2015 at a Glance | 7.3 | 0 | Citations (PDF) |
| 593 | Tako-tsubo cardiomyopathy in two sisters: a chance finding or familial predisposition? | 2.8 | 15 | Citations (PDF) |
| 594 | Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations | 3.3 | 3 | Citations (PDF) |
| 595 | Effectiveness of MitraClip Therapy in Patients with Refractory Heart Failure | 1.3 | 23 | Citations (PDF) |
| 596 | Worsening Heart Failure Following Admission for Acute Heart Failure | 4.4 | 50 | Citations (PDF) |
| 597 | Role of different vascular approaches on transcatheter aortic valve implantation outcome | 1.2 | 24 | Citations (PDF) |
| 598 | Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models | 2.9 | 68 | Citations (PDF) |
| 599 | Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month mortality, independent of N-terminal pro–B-type natriuretic peptide levels: An individual patient data analysis | 2.9 | 20 | Citations (PDF) |
| 600 | Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure | 4.4 | 22 | Citations (PDF) |
| 601 | Competing Risk of Cardiac Status and Renal Function During Hospitalization for Acute Decompensated Heart Failure | 4.4 | 49 | Citations (PDF) |
| 602 | Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation | 2.0 | 35 | Citations (PDF) |
| 603 | Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure | 2.7 | 71 | Citations (PDF) |
| 604 | Ivabradine during cardiogenic shock: A clinical case and review of the literature | 2.1 | 11 | Citations (PDF) |
| 605 | A combined clinical and biomarker approach to predict diuretic response in acute heart failure | 2.8 | 39 | Citations (PDF) |
| 606 | Predictors of Postdischarge Outcomes From Information Acquired Shortly After Admission for Acute Heart Failure | 4.4 | 118 | Citations (PDF) |
| 607 | Worsening Heart Failure, a Critical Event During Hospital Admission for Acute Heart Failure: Results from the VERITAS Study | 7.3 | 33 | Citations (PDF) |
| 608 | Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial | 2.2 | 99 | Citations (PDF) |
| 609 | A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure | 2.2 | 119 | Citations (PDF) |
| 610 | Reply | 2.0 | 0 | Citations (PDF) |
| 611 | Evaluation of Ascending Aorta Wall in Rheumatoid Arthritis by Tissue and Strain Doppler Imaging During Anti–Tumor Necrosis Factor‐α Therapy | 2.0 | 10 | Citations (PDF) |
| 612 | Diuretic Response in Patients with Acute Decompensated Heart Failure: Characteristics and Clinical Outcome—an Analysis from RELAX-AHF | 7.3 | 151 | Citations (PDF) |
| 613 | Noninvasive Assessment of Endothelial Function: The Classic Methods and the New Peripheral Arterial Tonometry | 1.7 | 21 | Citations (PDF) |
| 614 | Effects of Spironolactone on Long-term Mortality and Morbidity in Patients With Heart Failure and Mild or No Symptoms | 0.9 | 32 | Citations (PDF) |
| 615 | Transcatheter treatment of chronic mitral regurgitation with the MitraClip system | 1.2 | 9 | Citations (PDF) |
| 616 | Diuretic response in acute heart failure: clinical characteristics and prognostic significance | 2.2 | 342 | Citations (PDF) |
| 617 | Is There a Role for Ivabradine Beyond its Conventional Use? | 5.3 | 10 | Citations (PDF) |
| 618 | Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure | 4.4 | 62 | Citations (PDF) |
| 619 | New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes | 2.2 | 331 | Citations (PDF) |
| 620 | Role of Aliskiren on Arterial Stiffness and Endothelial Function in Patients With Primary Hypertension | 2.0 | 21 | Citations (PDF) |
| 621 | A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ÉLAN-HF ScoreHeart, 2014, 100, 115-125 | 3.9 | 133 | Citations (PDF) |
| 622 | Effect of Serelaxin on Mode of Death in Acute Heart Failure | 2.3 | 65 | Citations (PDF) |
| 623 | Elastic Aortic Properties in Patients with X Syndrome | 0.9 | 7 | Citations (PDF) |
| 624 | Body Mass Index and Mortality in Acutely Decompensated Heart Failure Across the World | 2.3 | 240 | Citations (PDF) |
| 625 | Effects of transcatheter aortic valve implantation on ascending aorta wall elastic properties: Tissue Doppler imaging and strain Doppler echocardiography study | 0.6 | 6 | Citations (PDF) |
| 626 | Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives | 0.6 | 34 | Citations (PDF) |
| 627 | In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry | 2.2 | 109 | Citations (PDF) |
| 628 | Liver Function, In-Hospital, and Post-Discharge Clinical Outcome in Patients With Acute Heart Failure—Results From the Relaxin for the Treatment of Patients With Acute Heart Failure Study | 1.8 | 46 | Citations (PDF) |
| 629 | International Differences in Clinical Characteristics, Management, and Outcomes in Acute Heart Failure Patients: Better Short-Term Outcomes in Patients Enrolled in Eastern Europe and Russia in the PROTECT Trial | 7.3 | 73 | Citations (PDF) |
| 630 | Treatment with inotropes and related prognosis in acute heart failure: Contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry | 1.1 | 27 | Citations (PDF) |
| 631 | Echocardiographic elastic properties of ascending aorta and their relationship with exercise capacity in patients with non-ischemic dilated cardiomyopathy | 0.6 | 4 | Citations (PDF) |
| 632 | Effects of Oral Amino Acid Supplements on Functional Capacity in Patients with Chronic Heart Failure | 2.9 | 44 | Citations (PDF) |
| 633 | Amino acids and derivatives, a new treatment of chronic heart failure? | 3.3 | 38 | Citations (PDF) |
| 634 | Need for Ongoing Anti Arrhythmic Drugs After Ablation of Atrial Fibrillation. Review | 2.6 | 2 | Citations (PDF) |
| 635 | Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF | 2.2 | 61 | Citations (PDF) |
| 636 | Prognostic Value of Indeterminable Anaerobic Threshold in Heart Failure | 4.4 | 69 | Citations (PDF) |
| 637 | Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome | 2.2 | 20 | Citations (PDF) |
| 638 | Haemodynamic Effects, Safety, and Pharmacokinetics of Human Stresscopin in Heart Failure with Reduced Ejection Fraction | 7.3 | 30 | Citations (PDF) |
| 639 | Risk Following Hospitalization in Stable Chronic Systolic Heart Failure | 7.3 | 44 | Citations (PDF) |
| 640 | Association Between Elevated Blood Glucose and Outcome in Acute Heart Failure | 2.3 | 122 | Citations (PDF) |
| 641 | The Potential Role of Nonpharmacologic Electrophysiology-Based Interventions in Improving Outcomes in Patients Hospitalized for Heart Failure | 1.9 | 0 | Citations (PDF) |
| 642 | Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: A multiparametric approach to heart failure prognosis | 2.2 | 215 | Citations (PDF) |
| 643 | Severe heart failure prognosis evaluation for transplant selection in the era of beta-blockers: Role of peak oxygen consumption | 2.2 | 27 | Citations (PDF) |
| 644 | The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure | 2.3 | 172 | Citations (PDF) |
| 645 | Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study | 2.2 | 218 | Citations (PDF) |
| 646 | Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program | 2.3 | 420 | Citations (PDF) |
| 647 | Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial | 62.1 | 871 | Citations (PDF) |
| 648 | Sex-Specific Acute Heart Failure Phenotypes and Outcomes from PROTECT | 7.3 | 61 | Citations (PDF) |
| 649 | Adrenergic receptor gene polymorphism and left ventricular reverse remodelling after cardiac resynchronization therapy: preliminary results | 2.0 | 17 | Citations (PDF) |
| 650 | Is There a Rationale for Antiplatelet Therapy in Acute Heart Failure? | 4.4 | 8 | Citations (PDF) |
| 651 | Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates? | 4.4 | 111 | Citations (PDF) |
| 652 | Multicenter Prospective Observational Study on Acute and Chronic Heart Failure | 4.4 | 194 | Citations (PDF) |
| 653 | Are Hospitalized or Ambulatory Patients with Heart Failure Treated in Accordance with European Society of Cardiology Guidelines? Evidence from 12 440 Patients of the ESC Heart Failure Long-Term Registry | 7.3 | 613 | Citations (PDF) |
| 654 | Clinical Outcome Endpoints in Heart Failure Trials: A European Society of Cardiology Heart Failure Association Consensus Document | 7.3 | 211 | Citations (PDF) |
| 655 | Effect of Oral Digoxin in High-Risk Heart Failure Patients: A Pre-Specified Subgroup Analysis of the DIG Trial | 7.3 | 95 | Citations (PDF) |
| 656 | Heart Failure in Elderly Patients: Distinctive Features and Unresolved Issues | 7.3 | 163 | Citations (PDF) |
| 657 | EUR
Observational
Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot) | 7.3 | 724 | Citations (PDF) |
| 658 | Task force on | 1.2 | 92 | Citations (PDF) |
| 659 | ??-Blockade in Heart Failure | 2.5 | 13 | Citations (PDF) |
| 660 | Nebivolol | 11.4 | 57 | Citations (PDF) |
| 661 | The European CRT Survey: 1 Year (9–15 Months) Follow-Up Results | 7.3 | 92 | Citations (PDF) |
| 662 | Effects of the Long-Term Administration of Nebivolol on the Clinical Symptoms, Exercise Capacity, and Left Ventricular Function of Patients with Diastolic Dysfunction: Results of the ELANDD Study | 7.3 | 190 | Citations (PDF) |
| 663 | The PROTECT In-Hospital Risk Model: 7-Day Outcome in Patients Hospitalized with Acute Heart Failure and Renal Dysfunction | 7.3 | 121 | Citations (PDF) |
| 664 | Is Worsening Renal Function an Ominous Prognostic Sign in Patients With Acute Heart Failure? | 4.4 | 467 | Citations (PDF) |
| 665 | Response to Letter Regarding Article, “Is Worsening Renal Function an Ominous Prognostic Sign in Patients With Acute Heart Failure? The Role of Congestion and Its Interaction With Renal Function” | 4.4 | 3 | Citations (PDF) |
| 666 | Elastic properties of the ascending aorta in patients with α1-antitrypsin deficiency (Z homozygotes)Heart, 2012, 98, 1354-1358 | 3.9 | 28 | Citations (PDF) |
| 667 | Echocardiographic Evaluation of Asymptomatic Patients Affected by Rheumatoid Arthritis | 1.7 | 16 | Citations (PDF) |
| 668 | Troponin I in Acute Decompensated Heart Failure: Insights from the ASCEND-HF Study | 7.3 | 108 | Citations (PDF) |
| 669 | Acute Heart Failure Patient Profiles, Management and In-Hospital Outcome: Results of the Italian Registry on Heart Failure Outcome | 7.3 | 121 | Citations (PDF) |
| 670 | The role of the kidney in heart failure | 2.2 | 237 | Citations (PDF) |
| 671 | Design of the RELAXin in Acute Heart Failure Study | 2.9 | 62 | Citations (PDF) |
| 672 | Hyponatremia and Long-Term Outcomes in Chronic Heart Failure—An Observational Study From the Duke Databank for Cardiovascular Diseases | 1.8 | 63 | Citations (PDF) |
| 673 | The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment | 2.8 | 42 | Citations (PDF) |
| 674 | Functional and Hemodynamic Cardiac Determinants of Exercise Capacity in Patients With Systolic Heart Failure | 1.8 | 20 | Citations (PDF) |
| 675 | Pioglitazone Improves In Vitro Viability and Function of Endothelial Progenitor Cells from Individuals with Impaired Glucose Tolerance | 2.3 | 42 | Citations (PDF) |
| 676 | Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation | 2.8 | 42 | Citations (PDF) |
| 677 | Six‐year prognosis of diabetic patients with coronary artery disease | 3.0 | 12 | Citations (PDF) |
| 678 | Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure | 3.3 | 55 | Citations (PDF) |
| 679 | Anticoagulation in heart failure: current status and future direction | 3.3 | 28 | Citations (PDF) |
| 680 | Soluble guanylate cyclase: a potential therapeutic target for heart failure | 3.3 | 148 | Citations (PDF) |
| 681 | Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions | 3.3 | 53 | Citations (PDF) |
| 682 | Early Drop in Systolic Blood Pressure and Worsening Renal Function in Acute Heart Failure: Renal Results of Pre-RELAX-AHF | 7.3 | 115 | Citations (PDF) |
| 683 | Clinical Trials in Acute Heart Failure: Simpler Solutions to Complex Problems. Consensus Document Arising from a European Society of Cardiology Cardiovascular Round-Table Think Tank on Acute Heart Failure, 12 May 2009 | 7.3 | 32 | Citations (PDF) |
| 684 | Effects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction | 2.3 | 131 | Citations (PDF) |
| 685 | Elastic properties of the ascending aorta in patients with rheumatoid arthritis | 2.2 | 7 | Citations (PDF) |
| 686 | Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure | 1.2 | 66 | Citations (PDF) |
| 687 | Old and New Intravenous Inotropic Agents in the Treatment of Advanced Heart Failure | 5.6 | 20 | Citations (PDF) |
| 688 | Anaemia and heart failure | 1.3 | 1 | Citations (PDF) |
| 689 | Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF | 2.8 | 13 | Citations (PDF) |
| 690 | Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial | 2.2 | 127 | Citations (PDF) |
| 691 | Thromboembolism and Antithrombotic Therapy in Patients With Heart Failure in Sinus Rhythm | 4.4 | 34 | Citations (PDF) |
| 692 | Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure | 4.4 | 84 | Citations (PDF) |
| 693 | Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study | 2.2 | 87 | Citations (PDF) |
| 694 | Can we prevent or treat renal dysfunction in acute heart failure? | 3.3 | 16 | Citations (PDF) |
| 695 | Can we prevent or treat renal dysfunction in chronic heart failure? | 3.3 | 9 | Citations (PDF) |
| 696 | Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment | 3.3 | 30 | Citations (PDF) |
| 697 | Dyspnoea in Patients with Acute Heart Failure: An Analysis of its Clinical Course, Determinants, and Relationship to 60-Day Outcomes in the PROTECT Pilot Study | 7.3 | 62 | Citations (PDF) |
| 698 | Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes | 4.4 | 138 | Citations (PDF) |
| 699 | Relaxin: Review of Biology and Potential Role in Treating Heart Failure | 2.9 | 131 | Citations (PDF) |
| 700 | Role of Beta-Adrenergic Receptor Gene Polymorphisms in the Long-Term Effects of Beta-Blockade with Carvedilol in Patients with Chronic Heart Failure | 2.1 | 64 | Citations (PDF) |
| 701 | Effect of Spironolactone on Left Ventricular Ejection Fraction and Volumes in Patients With Class I or II Heart Failure | 1.8 | 73 | Citations (PDF) |
| 702 | Measurement of the Myocardial Performance Index in Ambulatory Patients with Heart Failure: Correlation with Other Clinical and Echocardiographic Parameters and Independent Prognostic Value | 0.9 | 6 | Citations (PDF) |
| 703 | n-3 Pufas and Cardiovascular Disease Prevention | 1.0 | 30 | Citations (PDF) |
| 704 | Dyspnoea and Worsening Heart Failure in Patients with Acute Heart Failure: Results from the Pre-RELAX-AHF Study | 7.3 | 91 | Citations (PDF) |
| 705 | Haemodynamic Effects of Rolofylline in the Treatment of Patients with Heart Failure and Impaired Renal Function | 7.3 | 16 | Citations (PDF) |
| 706 | EUR
Observational
Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot) | 7.3 | 376 | Citations (PDF) |
| 707 | Ventilatory Efficiency and the Selection of Patients for Heart Transplantation | 4.4 | 55 | Citations (PDF) |
| 708 | Acute heart failure: Multiple clinical profiles and mechanisms require tailored therapy | 2.2 | 66 | Citations (PDF) |
| 709 | Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function | 1.8 | 79 | Citations (PDF) |
| 710 | The Effects of Adenosine A1 Receptor Antagonism in Patients With Acute Decompensated Heart Failure and Worsening Renal Function: The REACH UP Study | 1.8 | 23 | Citations (PDF) |
| 711 | Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program | 2.9 | 223 | Citations (PDF) |
| 712 | Rolofylline, an Adenosine A1−Receptor Antagonist, in Acute Heart Failure | 34.5 | 497 | Citations (PDF) |
| 713 | Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade | 2.6 | 8 | Citations (PDF) |
| 714 | Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials | 2.2 | 123 | Citations (PDF) |
| 715 | Palliative Care in Heart Failure: A Position Statement from the Palliative Care Workshop of the Heart Failure Association of the European Society of Cardiology | 7.3 | 492 | Citations (PDF) |
| 716 | Years-Needed-To-Treat to Add 1 Year of Life: A New Metric to Estimate Treatment Effects in Randomized Trials | 7.3 | 11 | Citations (PDF) |
| 717 | Response to the Letter of Hester Den Ruijter and Ruben Coronel Regarding the Article “The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy” | 2.1 | 0 | Citations (PDF) |
| 718 | Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na–K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? | 3.3 | 47 | Citations (PDF) |
| 719 | Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond | 3.3 | 91 | Citations (PDF) |
| 720 | Nuclear cardiology and heart failure | 5.5 | 10 | Citations (PDF) |
| 721 | Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF) | 2.9 | 37 | Citations (PDF) |
| 722 | Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group | 2.9 | 48 | Citations (PDF) |
| 723 | Micronutrient Deficiencies | 2.3 | 133 | Citations (PDF) |
| 724 | Highlights of the 2009 Scientific Sessions of the European Society of Cardiology | 2.3 | 6 | Citations (PDF) |
| 725 | Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study | 62.1 | 408 | Citations (PDF) |
| 726 | Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study | 2.8 | 14 | Citations (PDF) |
| 727 | CA 125 Tumoral Marker Plasma Levels Relate to Systolic and Diastolic Ventricular Function and to the Clinical Status of Patients with Chronic Heart Failure | 0.9 | 21 | Citations (PDF) |
| 728 | Improvements in Signs and Symptoms During Hospitalization for Acute Heart Failure Follow Different Patterns and Depend on the Measurement Scales Used: An International, Prospective Registry to Evaluate the Evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE-AHF) | 1.8 | 44 | Citations (PDF) |
| 729 | The PROTECT Pilot Study: A Randomized, Placebo-Controlled, Dose-Finding Study of the Adenosine A1 Receptor Antagonist Rolofylline in Patients With Acute Heart Failure and Renal Impairment | 1.8 | 165 | Citations (PDF) |
| 730 | Right Ventricular Thrombus and Pulmonary Thromboembolism/Thrombosis in Behçet's Disease: A Case Report | 3.4 | 11 | Citations (PDF) |
| 731 | Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation | 2.2 | 257 | Citations (PDF) |
| 732 | Treatment of heart failure in the elderly: never say it's too late | 2.2 | 19 | Citations (PDF) |
| 733 | The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy | 2.1 | 65 | Citations (PDF) |
| 734 | Vasodilators in the treatment of acute heart failure: what we know, what we don’t | 3.3 | 54 | Citations (PDF) |
| 735 | Relaxin, a pleiotropic vasodilator for the treatment of heart failure | 3.3 | 120 | Citations (PDF) |
| 736 | Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology | 2.2 | 1,801 | Citations (PDF) |
| 737 | Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) | 2.2 | 1,151 | Citations (PDF) |
| 738 | Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology | 7.3 | 355 | Citations (PDF) |
| 739 | Prognostic Importance of Plasma NT-Pro BNP in Chronic Heart Failure in Patients Treated with a β-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) Trial | 7.3 | 72 | Citations (PDF) |
| 740 | Effect of Carvedilol and Metoprolol on the Mode of Death in Patients with Heart Failure | 7.3 | 38 | Citations (PDF) |
| 741 | Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET | 7.3 | 94 | Citations (PDF) |
| 742 | The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T | 7.3 | 148 | Citations (PDF) |
| 743 | Treatment of Advanced Chronic Heart Failure with Normal Left Ventricular Ejection Fraction. Response to the letter by Dr. Martinez-Selles | 7.3 | 2 | Citations (PDF) |
| 744 | β-blocker therapy of heart failure: an update | 2.1 | 4 | Citations (PDF) |
| 745 | Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure | 16.5 | 340 | Citations (PDF) |
| 746 | Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: Results of the oral enoximone in intravenous inotrope-dependent subjects trial | 2.9 | 26 | Citations (PDF) |
| 747 | Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure | 2.3 | 63 | Citations (PDF) |
| 748 | The Safety of Amiodarone in Patients With Heart Failure | 1.8 | 55 | Citations (PDF) |
| 749 | Anemia and Heart Failure: A Cause of Progression or Only a Consequence? | 2.0 | 1 | Citations (PDF) |
| 750 | Long-Term Survival of Patients With Heart Failure and Ventricular Conduction Delay Treated With Cardiac Resynchronization Therapy | 1.8 | 92 | Citations (PDF) |
| 751 | ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death | 2.3 | 1,331 | Citations (PDF) |
| 752 | A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the “Patient Journey”) in Patients With Heart Failure | 2.3 | 72 | Citations (PDF) |
| 753 | ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death—Executive Summary | 2.3 | 158 | Citations (PDF) |
| 754 | ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary | 2.3 | 1,070 | Citations (PDF) |
| 755 | ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society | 2.0 | 665 | Citations (PDF) |
| 756 | Optimal Pharmacologic and Non-pharmacologic Management of Cardiac Transplant Candidates: Approaches to Be Considered Prior to Transplant Evaluation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates—2006 | 1.1 | 64 | Citations (PDF) |
| 757 | Endothelial Damage Due to Air Pollution | 2.0 | 0 | Citations (PDF) |
| 758 | Managing heart failure in the very old | 0.6 | 0 | Citations (PDF) |
| 759 | Usefulness of cardiac calcification on two-dimensional echocardiography for distinguishing ischaemic from nonischaemic dilated cardiomyopathy: a preliminary report | 1.2 | 6 | Citations (PDF) |
| 760 | Prognostic Value of Cardiopulmonary Exercise Variables in Chronic Heart Failure Patients With or Without Beta-Blocker Therapy | 1.8 | 37 | Citations (PDF) |
| 761 | ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Associat | 2.2 | 469 | Citations (PDF) |
| 762 | The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET | 2.2 | 219 | Citations (PDF) |
| 763 | Role of β1- and α2c-adrenergic receptor polymorphisms and their combination in heart failure: A case-control study | 7.3 | 29 | Citations (PDF) |
| 764 | ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death | 18.0 | 1,062 | Citations (PDF) |
| 765 | ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary | 18.0 | 297 | Citations (PDF) |
| 766 | ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart R | 2.0 | 558 | Citations (PDF) |
| 767 | ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation–executive summary | 2.2 | 622 | Citations (PDF) |
| 768 | ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation | 18.0 | 2,152 | Citations (PDF) |
| 769 | Exchange of β‐blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial) | 7.3 | 30 | Citations (PDF) |
| 770 | Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology | 2.2 | 1,135 | Citations (PDF) |
| 771 | Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET | 2.2 | 583 | Citations (PDF) |
| 772 | Symptoms in Patients With Heart Failure are Prognostic Predictors: Insights From COMET | 1.8 | 173 | Citations (PDF) |
| 773 | Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial | 2.2 | 164 | Citations (PDF) |
| 774 | Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET | 2.9 | 78 | Citations (PDF) |
| 775 | Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS) | 2.9 | 67 | Citations (PDF) |
| 776 | Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca aguda. Versión resumida | 1.1 | 56 | Citations (PDF) |
| 777 | ESSENTIAL – The Studies of Oral Enoximone Therapy in Advanced Heart Failure | 1.8 | 2 | Citations (PDF) |
| 778 | Rationale and Design of the Enoximone Clinical Trials Program | 1.8 | 27 | Citations (PDF) |
| 779 | Current guidelines in the pharmacological management of chronic heart failure. | 6.1 | 3 | Citations (PDF) |
| 780 | Left internal thoracic artery−radial artery composite grafts as the technique of choice for myocardial revascularization in elderly patients: a prospective randomized evaluation | 2.6 | 78 | Citations (PDF) |
| 781 | A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET) | 2.1 | 11 | Citations (PDF) |
| 782 | Beta-Blockers in Heart Failure: Are Pharmacological Differences Clinically Important? | 3.3 | 50 | Citations (PDF) |
| 783 | Role of ?1- and ?2-adrenoceptor polymorphisms in heart failure: a case-control study | 2.2 | 48 | Citations (PDF) |
| 784 | Serum levels of carbohydrate antigen 125 in patients with chronic heart failure | 2.3 | 163 | Citations (PDF) |
| 785 | Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial | 62.1 | 1,740 | Citations (PDF) |
| 786 | Off-pump coronary artery bypass surgery technique for total arterial myocardial revascularization: a prospective randomized study | 2.3 | 114 | Citations (PDF) |
| 787 | Marked improvement in left ventricular ejection fraction during long-term β-blockade in patients with chronic heart failure: Clinical correlates and prognostic significance | 2.9 | 112 | Citations (PDF) |
| 788 | Fibroblast Growth Factor Receptor-1 Is Essential for In Vitro Cardiomyocyte Development | 13.1 | 123 | Citations (PDF) |
| 789 | Is total arterial myocardial revascularization with composite grafts a safe and useful procedure in the elderly?☆ | 1.4 | 23 | Citations (PDF) |
| 790 | Total Arterial Myocardial Revascularization With Composite Grafts Improves Results of Coronary Surgery in Elderly: A Prospective Randomized Comparison With Conventional Coronary Artery Bypass Surgery | 18.0 | 70 | Citations (PDF) |
| 791 | β‐Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long‐term effects of atenolol vs. nebivolol | 7.3 | 121 | Citations (PDF) |
| 792 | Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus | 7.3 | 21 | Citations (PDF) |
| 793 | Angiotensin-converting-enzyme gene polymorphism and heart failure: a case–control study | 1.9 | 15 | Citations (PDF) |
| 794 | Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET | 7.3 | 70 | Citations (PDF) |
| 795 | Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure | 2.3 | 233 | Citations (PDF) |
| 796 | Dislodgment of the lead in coronary sinus for left ventricular pacing: Is this event predictable on the basis of any parameters evaluable at implant? | 2.0 | 0 | Citations (PDF) |
| 797 | Selective or nonselective β-adrenergic blockade in patients with congestive heart failure | 2.9 | 2 | Citations (PDF) |
| 798 | A rationale for the use of β-blockers as standard treatment for heart failure | 2.9 | 62 | Citations (PDF) |
| 799 | Title is missing! | 3.3 | 3 | Citations (PDF) |
| 800 | Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure | 2.3 | 124 | Citations (PDF) |
| 801 | Maximal and Submaximal Exercise Testing in Heart Failure | 2.0 | 4 | Citations (PDF) |
| 802 | Maximal and Submaximal Exercise Testing in Heart Failure | 2.0 | 13 | Citations (PDF) |
| 803 | Pharmacological activity of the new calcium antagonist, lacidipine, on isolated preparations | 0.0 | 2 | Citations (PDF) |
| 804 | Role of exercise ventilation in the limitation of functional capacity in patients with congestive heart failure | 7.0 | 13 | Citations (PDF) |
| 805 | Electrolyte disturbances in chronic heart failure: Metabolic and clinical aspects | 2.0 | 20 | Citations (PDF) |
| 806 | Clinical efficacy of ibopamine in patients with chronic heart failure | 2.0 | 2 | Citations (PDF) |
| 807 | Dopaminergic Drugs in Congestive Heart Failure | 2.0 | 9 | Citations (PDF) |
| 808 | Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy | 2.3 | 309 | Citations (PDF) |
| 809 | Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: Hyponatremia, hypokalemia, and hypomagnesemia | 2.9 | 184 | Citations (PDF) |
| 810 | Pulmonary hypertension and systemic hypotension as limitations to exercise in chronic heart failure | 1.8 | 7 | Citations (PDF) |
| 811 | Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure | 2.1 | 9 | Citations (PDF) |
| 812 | Dynamic Cardiomyoplasty as an Effective Therapy for Dilated Cardiomyopathy | 0.9 | 22 | Citations (PDF) |
| 813 | Combined invasive and noninvasive study of left ventricular systolic and diastolic function following acute administration of cicloprolol to subjects with normal cardiac function | 2.1 | 0 | Citations (PDF) |
| 814 | Exercise hyperventilation chronic congestive heart failure, and its relation to functional capacity and hemodynamics | 1.8 | 182 | Citations (PDF) |
| 815 | Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure | 1.8 | 20 | Citations (PDF) |
| 816 | Assessment of peak oxygen consumption, lactate and ventilatory thresholds and correlation with resting and exercise hemodynamic data in chronic congestive heart failure | 1.8 | 81 | Citations (PDF) |
| 817 | Clinical Pharmacology of Inodilators | 2.0 | 2 | Citations (PDF) |
| 818 | Efficacy of Ibopamine Treatment in Patients with Advanced Heart Failure | 2.0 | 0 | Citations (PDF) |
| 819 | Diagnosis of acute myocardial infarction by indium-111 antimyosin antibodies and correlation with the traditional techniques for the evaluation of extent and localization | 1.8 | 51 | Citations (PDF) |
| 820 | Dopamine receptors in the stellate ganglion of the dog | 4.3 | 6 | Citations (PDF) |
| 821 | Inhibition of Aldosterone Secretion by Dopamine, Ibopamine, and Dihydroergotoxine in Patients with Congestive Heart Failure | 2.0 | 1 | Citations (PDF) |
| 822 | Clinical Pharmacology of Inodilators | 2.0 | 11 | Citations (PDF) |
| 823 | Inhibition of Aldosterone Secretion by Dopamine, Ibopamine, and Dihydroergotoxine in Patients with Congestive Heart Failure | 2.0 | 14 | Citations (PDF) |
| 824 | Efficacy of Ibopamine Treatment in Patients with Advanced Heart Failure | 2.0 | 7 | Citations (PDF) |
| 825 | A randomized double-blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant essential hypertension | 2.1 | 1 | Citations (PDF) |
| 826 | Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure | 2.1 | 13 | Citations (PDF) |
| 827 | Diagnostic accuracy of rest-exercise first pass ventriculography with a fast single crystal gamma camera in detecting coronary artery disease | 1.0 | 3 | Citations (PDF) |
| 828 | Hemodynamic advantage of combined administration of oral ibopamine and nitroprusside in patients with ischemic and idiopathic congestive cardiomyopathy | 2.0 | 9 | Citations (PDF) |
| 829 | Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure. | 2.5 | 6 | Citations (PDF) |
| 830 | Title is missing! 0 | | 1 | Citations (PDF) |
| 831 | Remote Pulmonary Artery Pressure-Guided Management of Patients with Heart Failure: A Clinical Consensus Statement of the Heart Failure Association (HFA) of the ESC | 7.3 | 18 | Citations (PDF) |
| 832 | Quality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology | 2.0 | 14 | Citations (PDF) |
| 833 | Severe acute kidney injury in the intensive care unit: step-to-step management | 1.0 | 3 | Citations (PDF) |
| 834 | Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement | 2.2 | 56 | Citations (PDF) |
| 835 | Guideline-Directed Medical Therapy Use in the STRONG-HF Trial | 4.4 | 2 | Citations (PDF) |
| 836 | Heart failure with reduced ejection fraction and ventricular secondary mitral regurgitation: a holistic approach | 2.2 | 7 | Citations (PDF) |
| 837 | Heart Failure Hospitalizations and Clinical Outcomes in Patients Undergoing Tricuspid Transcatheter Edge-To-Edge Repair: Insights from EuroTR | 7.3 | 8 | Citations (PDF) |
| 838 | Impact of glomerular filtration rate estimation formulas on MECKI score performance and prognostic accuracy in heart failure: the MECKI-RENAL study | 3.7 | 0 | Citations (PDF) |
| 839 | Heart Failure-Attributed Mortality in Europe, 2012–2021 | 7.3 | 7 | Citations (PDF) |
| 840 | Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study | 2.2 | 19 | Citations (PDF) |
| 841 | Moderate Secondary Mitral Regurgitation | 2.3 | 1 | Citations (PDF) |
| 842 | Heart Failure 2025 Congress: a recent remarkable success in heart failure | 2.2 | 0 | Citations (PDF) |
| 843 | Mapping of Current Practices of Palliative Care for Patients with Heart Failure Throughout Europe: A Scoping Review | 3.1 | 3 | Citations (PDF) |
| 844 | Management of Aortic Stenosis and Chronic Heart Failure: A Clinical Consensus Statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC | 7.3 | 5 | Citations (PDF) |
| 845 | Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin Cardiomyopathy | 4.0 | 4 | Citations (PDF) |
| 846 | Priority measures for implementation: an ESC pilot linking guidelines to practice | 3.7 | 0 | Citations (PDF) |
| 847 | Mitral transcatheter edge-to-edge repair and outcomes according to baseline health status: the RESHAPE-HF2 trial | 2.2 | 4 | Citations (PDF) |
| 848 | Combination Diuretic Therapy in Acute Heart Failure: A Systematic Review and Meta-Analysis | 7.3 | 2 | Citations (PDF) |
| 849 | Clinical and imaging phenotypes | 0.1 | 0 | Citations (PDF) |
| 850 | Evaluation of a combined symptom-based questionnaire and capillary natriuretic peptides testing for early detection of heart failure: a Heart Failure Awareness Days nationwide screening study (DEPIC FR) | 3.7 | 1 | Citations (PDF) |
| 851 | Real-world improved, remission, and recovered heart failure: long-term follow-up outcomes | 7.3 | 0 | Citations (PDF) |
| 852 | An expert opinion on heart failure in hypertensive heart disease | 7.3 | 0 | Citations (PDF) |
| 853 | Mitral regurgitation in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF | 7.3 | 0 | Citations (PDF) |
| 854 | Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF | 7.3 | 0 | Citations (PDF) |
| 855 | Understanding the Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Heart Failure | 3.7 | 3 | Citations (PDF) |
| 856 | Implementation of guideline-directed medical therapy in patients with heart failure and obesity:
European Journal of Heart Failure
expert consensus document | 7.3 | 2 | Citations (PDF) |
| 857 | 2025 ESC/EACTS valvular heart disease guidelines: practical updates on mitral and tricuspid regurgitation | 0.1 | 0 | Citations (PDF) |
| 858 | Evidence-based medical therapy after structural interventions: when remaining proactive for heart failure medications can save lives | 7.3 | 0 | Citations (PDF) |
| 859 | How to monitor disease progression in ATTR amyloid cardiomyopathy: Implications for clinical practice and trial design | 2.7 | 2 | Citations (PDF) |
| 860 | Effect of contemporary HFpEF therapies on diuretic management: decongestive role or disease modification? | 7.3 | 1 | Citations (PDF) |
| 861 | Worsening tricuspid regurgitation following a successful mitral valve procedure: how to manage | 0.1 | 0 | Citations (PDF) |
| 862 | The multidimensional needs of chronic heart failure patients and caregivers from a dyadic perspective: a scoping review | 3.3 | 0 | Citations (PDF) |
| 863 | Liver disease in tricuspid regurgitation: from congestion to cirrhosis | 7.3 | 0 | Citations (PDF) |
| 864 | Secondary mitral and tricuspid regurgitation in early HFrEF: the impact of contemporary medical therapy | 7.3 | 0 | Citations (PDF) |
| 865 | Recent advances in predicting and improving outcomes in patients undergoing transcatheter tricuspid valve intervention | 1.0 | 0 | Citations (PDF) |
| 866 | Fragility analysis of cardiovascular outcomes with finerenone in patients with Type 2 diabetes mellitus and chronic kidney disease | 7.3 | 0 | Citations (PDF) |
| 867 | Pleiotropic effects of bempedoic acid on endothelial function and arterial stiffness: a preliminary study | 1.2 | 1 | Citations (PDF) |
| 868 | Acute myocardial infarction vs acute decompensated heart failure in cardiogenic shock: a systematic review and meta-analysis of clinical phenotypes and mortality | 7.3 | 0 | Citations (PDF) |
| 869 | Longitudinal loop diuretic use in patients with HFrEF initiated with sodium–glucose cotransporter 2 inhibitors | 4.0 | 0 | Citations (PDF) |
